#BEGIN_DRUGCARD DB00200

# AHFS_Codes:
88:08.00

# ATC_Codes:
B03BA03
V03AB33

# Absorption:
Readily absorbed from the gastrointestinal tract, except in malabsorption syndromes. Vitamin B12 is absorbed in the lower half of the ileum.

# Biotransformation:
Primarily hepatic. Cobalamins are absorbed in the ileum and stored in the liver. They continuously undergo enterohepatic recycling via secretion in the bile. Part of a dose is excreted in the urine, most of it in the first 8 hours.

# Brand_Mixtures:
Acti-Hemosyn (Copper (Copper Malate, Copper Fumarate, Copper Citrate, Copper Succinate, Copper Glutarate) + D-Pantothenic Acid (Calcium D-Pantothenate) + Folic Acid + Iodine (Kelp) + Iron (Ferrous Fumarate, Ferrous Citrate, Iron Malate, Iron Glutarate, Ferrous Succinate) + Manganese (Manganese Citrate, Manganese Fumarate, Manganese Malate, Manganese Succinate, Manganese Glutarate) + Nicotinic Acid + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B12 (Cobamamide) + Vitamin B12 (Hydroxocobalamin) + Vitamin B2 (Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxal-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Calcium Ascorbate))
Acti-Hydroxo/Dibencoz 500 + Folic Acid Tab (Folic Acid + Vitamin B12 (Cobamamide, Hydroxocobalamin))
Acti-Multiveg (Beta-Carotene + Biotin + Calcium (Calcium Organic Complex) + Choline Citrate + Chromium (Chromium Organic Complex) + Copper (Copper Organic Complex) + D-Pantothenic Acid (Calcium D-Pantothenate) + Dl-Methionine + Folic Acid + Inositol + Iodine (Kelp) + Iron (Iron Organic Complex) + Magnesium (Magnesium Organic Complex) + Manganese (Manganese Organic Complex) + Molybdenum (Molybdenum Organic Complex) + Nicotinamide + Nicotinic Acid + Potassium (Potassium Organic Complex) + Selenium (Selenium Organic Complex) + Vanadium (Vanadium Organic Complex) + Vitamin a (Vitamin a Palmitate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B12 (Hydroxocobalamin) + Vitamin B2 + Vitamin B2 (Riboflavin 5'-Phosphate Sodium) + Vitamin B6 (Pyridoxal-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C + Vitamin D3 + Vitamin E (D-Alpha Tocopheryl Acid Succinate) + Zinc (Zinc Organic Complex))
Awesome Nubears (Beta-Carotene + Biotin + Calcium (Calcium Citrate) + Choline + Copper Fumarate (Copper Fumarate) + D-Pantothenic Acid (Calcium D-Pantothenate) + Folic Acid + Inositol (Choline Citrate) + Iodine (Kelp) + Iron (Ferrous Fumarate) + Magnesium (Magnesium Citrate) + Manganese (Manganese Citrate) + Nicotinamide + Potassium (Potassium Citrate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B12 (Hydroxocobalamin) + Vitamin B2 + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Calcium Ascorbate) + Vitamin D3 + Vitamin E (D-Alpha Tocopheryl Acid Succinate) + Zinc (Zinc Citrate))
Magnum Plus (Beta-Carotene + Biotin + Calcium (Calcium Citrate, Calcium Fumarate, Calcium Malate, Calcium Succinate, Calcium Glutarate) + Choline (Choline Citrate) + Chromium (Chromium Citrate, Chromium Fumarate, Chromium Malate, Chromium Succinate, Chromium Glutarate) + Copper (Copper Citrate, Copper Fumarate, Copper Malate, Copper Succinate, Copper Glutarate) + D-Alpha Tocopheryl Acid Succinate + D-Pantothenic Acid (Calcium D-Pantothenate) + Dl-Methionine + Folic Acid + Inositol + Iodine + Iron (Ferrous Fumarate, Iron Citrate, Iron Malate, Ferrous Succinate, Iron Glutarate) + Magnesium (Magnesium Citrate, Magnesium Fumarate, Magnesium Malate, Magnesium Succinate, Magnesium Glutarate, Magnesium Oxide) + Manganese (Manganese Citrate, Manganese Fumarate, Manganese Malate, Manganese Succinate, Manganese Glutarate) + Molybdenum (Molybdenum Citrate, Molybdenum Fumarate, Molybdenum Malate, Molybdenum Succinate, Molybdenum Glutarate) + Nicotinamide + Nicotinic Acid + Potassium (Potassium Citrate, Potassium Fumarate, Potassium Malate, Potassium Succinate, Potassium Glutarate) + Selenium (Selenium Citrate, Selenium Fumarate, Selenium Malate, Selenium Succinate, Selenium Glutarate) + Thiamine Hydrochloride + Vanadium (Vanadium Citrate, Vanadium Fumarate, Vanadium Malate, Vanadium Succinate, Vanadium Glutarate) + Vitamin a Palmitate + Vitamin B12 (Hydroxocobalamin, Dibencozide) + Vitamin B2 (Riboflavin, Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride, Pyridoxine 5' Phosphate) + Vitamin C (Ascorbic Acid, Calcium Ascorbate) + Vitamin D3 + Zinc (Zinc Citrate, Zinc Fumarate, Zinc Malate, Zinc Succinate, Zinc Glutarate))
The Legend (Beta-Carotene + Biotin + Calcium (Calcium Citrate, Calcium Fumarate, Calcium Malate, Calcium Succinate, Calcium Glutarate) + Choline (Choline Citrate) + Chromium (Chromium Citrate, Chromium Fumarate, Chromium Malate, Chromium Succinate, Chromium Glutarate) + D-Alpha Tocopheryl Acid Succinate + D-Pantothenic Acid (Calcium D-Pantothenate) + Dl-Methionine + Folic Acid + Inositol + Iodine (Kelp) + Magnesium (Magnesium Citrate, Magnesium Oxide, Magnesium Fumarate, Magnesium Malate, Magnesium Succinate, Magnesium Glutarate) + Manganese (Manganese Citrate, Manganese Fumarate, Manganese Malate, Manganese Succinate, Manganese Glutarate) + Molybdenum (Molybdenum Citrate, Molybdenum Fumarate, Molybdenum Succinate, Molybdenum Glutarate, Molybdenum Malate) + Nicotinamide + Nicotinic Acid + Potassium (Potassium Citrate, Potassium Fumarate, Potassium Malate, Potassium Succinate, Potassium Glutarate) + Selenium (Selenium Citrate, Selenium Fumarate, Selenium Malate, Selenium Succinate, Selenium Glutarate) + Thiamine Hydrochloride + Ubidecarenone + Vanadium (Vanadium Citrate, Vanadium Fumarate, Vanadium Malate, Vanadium Succinate, Vanadium Glutarate) + Vitamin a Palmitate + Vitamin B12 (Hydroxocobalamin, Dibencozide) + Vitamin B2 (Riboflavin, Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride, Pyridoxal-5-Phosphate) + Vitamin C (Ascorbic Acid, Calcium Ascorbate) + Vitamin D3 + Zinc (Zinc Citrate, Zinc Fumarate, Zinc Malate, Zinc Succinate, Zinc Glutarate))
The Ultimate One - 50 Plus Men (Beta-Carotene + Biotin + Calcium (Calcium Citrate, Calcium Fumarate, Calcium Malate, Calcium Succinate, Calcium Glutarate) + Choline (Choline Citrate) + Chromium (Chromium Citrate, Chromium Fumarate, Chromium Malate, Chromium Succinate, Chromium Glutarate) + D-Alpha Tocopheryl Acid Succinate + D-Pantothenic Acid (Calcium D-Pantothenate) + Dl-Methionine + Folic Acid + Inositol + Iodine (Kelp) + Magnesium (Magnesium Citrate, Magnesium Fumarate, Magnesium Malate, Magnesium Succinate, Magnesium Glutarate, Magnesium Oxide) + Manganese (Manganese Citrate, Manganese Fumarate, Manganese Malate, Manganese Succinate, Manganese Glutarate) + Molybdenum (Molybdenum Citrate, Molybdenum Fumarate, Molybdenum Malate, Molybdenum Succinate, Molybdenum Glutarate) + Nicotinamide + Nicotinic Acid + Potassium (Potassium Citrate, Potassium Fumarate, Potassium Malate, Potassium Succinate, Potassium Glutarate) + Selenium (Selenium Citrate, Selenium Fumarate, Selenium Malate, Selenium Succinate, Selenium Glutarate) + Thiamine Hydrochloride + Ubidecarenone + Vitamin a Palmitate + Vitamin B12 (Hydroxocobalamin, Dibencozide) + Vitamin B2 (Riboflavin, Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride, Pyridoxal-5-Phosphate) + Vitamin C (Ascorbic Acid, Calcium Ascorbate) + Vitamin D3 + Zinc (Zinc Citrate, Zinc Fumarate, Zinc Malate, Zinc Succinate, Zinc Glutarate))
The Ultimate One - 50 Plus Women (Beta-Carotene + Biotin + Calcium (Calcium Citrate, Calcium Fumarate, Calcium Malate, Calcium Succinate, Calcium Glutarate) + Choline (Choline Citrate) + Chromium (Chromium Citrate, Chromium Fumarate, Chromium Malate, Chromium Succinate, Chromium Glutarate) + Copper (Copper Citrate, Copper Fumarate, Copper Malate, Copper Succinate, Copper Glutarate) + D-Alpha Tocopheryl Acid Succinate + D-Pantothenic Acid (Calcium D-Pantothenate) + Dl-Methionine + Folic Acid + Inositol + Iodine (Kelp) + Magnesium (Magnesium Citrate, Magnesium Fumarate, Magnesium Malate, Magnesium Succinate, Magnesium Glutarate, Magnesium Oxide) + Manganese (Manganese Citrate, Manganese Fumarate, Manganese Malate, Manganese Succinate, Manganese Glutarate) + Molybdenum (Molybdenum Citrate, Molybdenum Fumarate, Molybdenum Malate, Molybdenum Succinate, Molybdenum Glutarate) + Nicotinamide + Nicotinic Acid + Potassium (Potassium Citrate, Potassium Fumarate, Potassium Malate, Potassium Succinate, Potassium Glutarate) + Selenium (Selenium Citrate, Selenium Fumarate, Selenium Malate, Selenium Succinate, Selenium Glutarate) + Thiamine Hydrochloride + Ubidecarenone + Vitamin a Palmitate + Vitamin B12 (Hydroxocobalamin, Dibencozide) + Vitamin B2 (Riboflavin, Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride, Pyridoxal-5-Phosphate) + Vitamin C (Ascorbic Acid, Calcium Ascorbate) + Vitamin D3 + Zinc (Zinc Citrate, Zinc Fumarate, Zinc Malate, Zinc Succinate, Zinc Glutarate))
The Ultimate One - Active Men Caplet (Beta-Carotene + Biotin + Calcium (Calcium Citrate, Calcium Fumarate, Calcium Malate, Calcium Succinate, Calcium Glutarate) + Choline (Choline Citrate) + Chromium (Chromium Citrate, Chromium Fumarate, Chromium Malate, Chromium Succinate, Chromium Glutarate) + D-Alpha Tocopheryl Acid Succinate + D-Pantothenic Acid (Calcium D-Pantothenate) + Dl-Methionine + Folic Acid + Inositol + Iodine (Kelp) + Iron (Iron Citrate, Ferrous Fumarate, Iron Malate, Ferrous Succinate, Iron Glutarate) + Magnesium (Magnesium Citrate, Magnesium Fumarate, Magnesium Malate, Magnesium Succinate, Magnesium Glutarate, Magnesium Oxide) + Manganese (Manganese Citrate, Manganese Fumarate, Manganese Succinate, Manganese Glutarate, Manganese Malate) + Molybdenum (Molybdenum Citrate, Molybdenum Fumarate, Molybdenum Malate, Molybdenum Succinate, Molybdenum Glutarate) + Nicotinamide + Nicotinic Acid + Potassium (Potassium Citrate, Potassium Fumarate, Potassium Malate, Potassium Succinate, Potassium Glutarate) + Selenium (Selenium Citrate, Selenium Fumarate, Selenium Malate, Selenium Succinate, Selenium Glutarate) + Thiamine Hydrochloride + Ubidecarenone + Vitamin a Palmitate + Vitamin B12 (Hydroxocobalamin, Dibencozide) + Vitamin B2 (Riboflavin, Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride, Pyridoxine 5' Phosphate) + Vitamin C (Calcium Ascorbate, Ascorbic Acid) + Vitamin D3 + Zinc (Zinc Citrate, Zinc Fumarate, Zinc Succinate, Zinc Glutarate, Zinc Malate))
The Ultimate One - Active Women (Beta-Carotene + Biotin + Calcium (Calcium Citrate, Calcium Fumarate, Calcium Malate, Calcium Succinate, Calcium Glutarate) + Choline (Choline Citrate) + Chromium (Chromium Citrate, Chromium Fumarate, Chromium Malate, Chromium Succinate, Chromium Glutarate) + Copper (Copper Malate, Copper Citrate, Copper Fumarate, Copper Succinate, Copper Glutarate) + D-Alpha Tocopheryl Acid Succinate + D-Pantothenic Acid (Calcium D-Pantothenate) + Dl-Methionine + Folic Acid + Inositol + Iodine (Kelp) + Iron (Ferrous Fumarate, Iron Citrate, Iron Malate, Ferrous Succinate, Iron Glutarate) + Magnesium (Magnesium Citrate, Magnesium Fumarate, Magnesium Malate, Magnesium Succinate, Magnesium Glutarate, Magnesium Oxide) + Manganese (Manganese Citrate, Manganese Fumarate, Manganese Malate, Manganese Succinate, Manganese Glutarate) + Molybdenum (Molybdenum Citrate, Molybdenum Fumarate, Molybdenum Malate, Molybdenum Succinate, Molybdenum Glutarate) + Nicotinamide + Nicotinic Acid + Potassium (Potassium Citrate, Potassium Fumarate, Potassium Malate, Potassium Succinate, Potassium Glutarate) + Selenium (Selenium Citrate, Selenium Fumarate, Selenium Malate, Selenium Succinate, Selenium Glutarate) + Thiamine Hydrochloride + Ubidecarenone + Vitamin a Palmitate + Vitamin B12 (Hydroxocobalamin, Dibencozide) + Vitamin B2 (Riboflavin, Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride, Pyridoxal-5-Phosphate) + Vitamin C (Ascorbic Acid, Calcium Ascorbate) + Vitamin D3 + Zinc (Zinc Citrate, Zinc Fumarate, Zinc Malate, Zinc Succinate, Zinc Glutarate))
The Ultimate One - Adult Women (Beta-Carotene + Biotin + Calcium (Calcium Citrate, Calcium Fumarate, Calcium Malate, Calcium Succinate, Calcium Glutarate) + Choline (Choline Citrate) + Chromium (Chromium Citrate, Chromium Fumarate, Chromium Malate, Chromium Succinate, Chromium Glutarate) + Copper (Copper Citrate, Copper Fumarate, Copper Malate, Copper Succinate, Copper Glutarate) + D-Alpha Tocopheryl Acid Succinate + D-Pantothenic Acid (Calcium D-Pantothenate) + Dl-Methionine + Folic Acid + Inositol + Iodine (Kelp) + Iron (Ferrous Fumarate, Iron Citrate, Iron Malate, Ferrous Succinate, Iron Glutarate) + Magnesium (Magnesium Citrate, Magnesium Fumarate, Magnesium Malate, Magnesium Succinate, Magnesium Glutarate, Magnesium Oxide) + Manganese (Manganese Citrate, Manganese Fumarate, Manganese Malate, Manganese Succinate, Manganese Glutarate) + Molybdenum (Molybdenum Citrate, Molybdenum Fumarate, Molybdenum Malate, Molybdenum Succinate, Molybdenum Glutarate) + Nicotinamide + Nicotinic Acid + Potassium (Potassium Citrate, Potassium Fumarate, Potassium Malate, Potassium Succinate, Potassium Glutarate) + Selenium (Selenium Citrate, Selenium Fumarate, Selenium Malate, Selenium Succinate, Selenium Glutarate) + Thiamine Hydrochloride + Ubidecarenone + Vitamin a Palmitate + Vitamin B12 (Hydroxocobalamin, Dibencozide) + Vitamin B2 (Riboflavin, Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride, Pyridoxal-5-Phosphate) + Vitamin C (Ascorbic Acid, Calcium Ascorbate) + Vitamin D3 + Zinc (Zinc Citrate, Zinc Fumarate, Zinc Malate, Zinc Succinate, Zinc Glutarate))
Vege 1 Daily (Beta-Carotene + Biotin + Calcium (Calcium Citrate, Calcium Fumarate, Calcium Malate, Calcium Succinate, Calcium Glutarate) + Choline Citrate + Chromium (Chromium Citrate, Chromium Fumarate, Chromium Malate, Chromium Succinate, Chromium Glutarate) + Copper (Copper Citrate, Copper Fumarate, Copper Malate, Copper Succinate, Copper Glutarate) + D-Pantothenic Acid (Calcium D-Pantothenate) + Dl-Methionine + Folic Acid + Inositol + Iodine (Kelp) + Iron (Ferrous Citrate, Ferrous Fumarate, Iron Malate, Ferrous Succinate, Iron Glutarate) + Magnesium (Magnesium Citrate, Magnesium Fumarate, Magnesium Malate, Magnesium Succinate, Magnesium Glutarate) + Manganese (Manganese Citrate, Manganese Fumarate, Manganese Malate, Manganese Succinate, Manganese Glutarate) + Molybdenum (Molybdenum Citrate, Molybdenum Fumarate, Molybdenum Malate, Molybdenum Succinate, Molybdenum Glutarate) + Nicotinamide + Nicotinic Acid + Potassium (Potassium Citrate, Potassium Fumarate, Potassium Malate, Potassium Succinate, Potassium Glutarate) + Selenium (Selenium Citrate, Selenium Fumarate, Selenium Malate, Selenium Succinate, Selenium Glutarate) + Vanadium (Vanadium Citrate, Vanadium Fumarate, Vanadium Malate, Vanadium Succinate, Vanadium Glutarate) + Vitamin a (Vitamin a Palmitate) + Vitamin B1 (Thiamine Hydrochloride) + Vitamin B12 (Hydroxocobalamin) + Vitamin B2 (Riboflavin-5-Phosphate) + Vitamin B6 (Pyridoxal-5-Phosphate) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Calcium Ascorbate) + Vitamin D3 + Vitamin E (D-Alpha Tocopheryl Acid Succinate) + Zinc (Zinc Citrate, Zinc Fumarate, Zinc Malate, Zinc Succinate, Zinc Glutarate))

# Brand_Names:
Acti-B12
Alpharedisol
Cyanokit
Hydro Cobex
Hydroxy Cobal

# CAS_Registry_Number:
13422-51-0

# ChEBI_ID:
27786

# Chemical_Formula:
C62H89CoN13O15P

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
543446

# Description:
Injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency. [PubChem]

# Dosage_Forms:
Liquid	Intramuscular
Solution	Oral

# Drug_Category:
Anti-anemic Agents
Hematinics
Nutritional Supplement
Vitamin B Complex

# Drug_Interactions:
Not Available

# Drug_Reference:
14585166	Seetharam B, Yammani RR: Cobalamin transport proteins and their cell-surface receptors. Expert Rev Mol Med. 2003 Jun 13;5(18):1-18.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Hydroxocobalamin

# HET_ID:
Not Available

# Half_Life:
Approximately 6 days (peak plasma concentration after 8-12 hours from oral administration)

# InChI_Identifier:
InChI=1S/C62H90N13O14P.Co.H2O/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;1H2/q;+3;/p-3/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1

# InChI_Key:
InChIKey=YOZNUFWCRFCGIH-WZHZPDAFSA-K

# Indication:
For treatment of pernicious anemia and the prevention and treatment of vitamin B12 deficiency arising from alcoholism, malabsorption, tapeworm infestation, celiac, hyperthyroidism, hepatic-biliary tract disease, persistent diarrhea, ileal resection, pancreatic cancer, renal disease, prolonged stress, vegan diets, macrobiotic diets or other restrictive diets. Also for the treatment of known or suspected cyanide poisoning.

# KEGG_Compound_ID:
C08230

# KEGG_Drug_ID:
D01027

# LIMS_Drug_ID:
200

# Mechanism_Of_Action:
Vitamin B12 exists in four major forms referred to collectively as cobalamins; deoxyadenosylcobalamin, methylcobalamin, hydroxocobalamin, and cyanocobalamin. Two of these, methylcobalamin and 5-deoxyadenosyl cobalamin, are primarily used by the body. Methionine synthase needs methylcobalamin as a cofactor. This enzyme is involved in the conversion of the amino acid homocysteine into methionine. Methionine in turn is required for DNA methylation. 5-Deoxyadenosyl cobalamin is a cofactor needed by the enzyme that converts L-methylmalonyl-CoA to succinyl-CoA. This conversion is an important step in the extraction of energy from proteins and fats. Furthermore, succinyl CoA is necessary for the production of hemoglobin, the substances that carries oxygen in red blood cells.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
1346.3551

# Molecular_Weight_Mono:
1345.567070949

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164768689

# Pharmacology:
Hydroxocobalamin is a synthetic, injectable form of Vitamin B12. Hydroxocobalamin is actually a precursor of two cofactors or vitamins (Vitamin B12 and Methylcobalamin) which are involved in various biological systems in man. Vitamin B12 is required for the conversion of methylmalonate to succinate. Deficiency of this enzyme could therefore interfere with the production of lipoprotein in myelin sheath tissue and so give rise to neurological lesions. The second cofactor, Methylcobalamin, is necessary for the conversion of homocysteine to methionine which is essential for the metabolism of folic acid. Deficiency of tetrahydrafolate leads to reduced synthesis of thymidylate resulting in reduced synthesis of DNA which is essential for cell maturation. Vitamin B12 is also concerned in the maintenance of sulphydryl groups in reduced form, deficiency leading to decreased amounts of reduced SH content of erythrocytes and liver cells. Overall, vitamin B12 acts as a coenzyme for various metabolic functions, including fat and carbohydrate metabolism and protein synthesis. It is necessary for growth, cell replication, hematopoiesis, and nucleoprotein as well as myelin synthesis. This is largely due to its effects on metabolism of methionine folic acid, and malonic acid.

# Predicted_LogP_Hydrophobicity:
2.53

# Predicted_LogS:
-5

# Predicted_Water_Solubility:
1.46e-02 g/l

# Primary_Accession_No:
DB00200

# Protein_Binding:
Very high (90%). Cobalamins are extensively bound to two specific plasma proteins called transcobalamin 1 and 2; 70% to transcobalamin 1, 5% to transcobalamin 2.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/cyanokit.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01022

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H]O[Co+]N1\C2=C(C)/C3=N/C(=C\C4=N\C(=C(C)/C5=N[C@@](C)([C@@]1([H])[C@H](CC(=O)N)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@H]1[C@@H](O)[C@H](O[C@@H]1CO)N1C=NC2=CC(C)=C(C)C=C12)[C@@](C)(CC(N)=O)[C@@H]5CCC(=O)N)\[C@@](C)(CC(=O)N)[C@@H]4CCC(=O)N)/C(C)(C)[C@@H]3CCC(=O)N

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Hydroxomin
Vitamin B-12b

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:10 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Hydroxocobalamin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
1744096	Kolhouse JF, Utley C, Stabler SP, Allen RH: Mechanism of conversion of human apo- to holomethionine synthase by various forms of cobalamin. J Biol Chem. 1991 Dec 5;266(34):23010-5.
18565	Tkachuck RD, Weinstein PP, Mueller JF: Metabolic fate of cyanocobalamin taken up by Spirometra mansonoides spargana. J Parasitol. 1977 Aug;63(4):694-700.
3812589	Rosenblatt DS, Thomas IT, Watkins D, Cooper BA, Erbe RW: Vitamin B12 responsive homocystinuria and megaloblastic anemia: heterogeneity in methylcobalamin deficiency. Am J Med Genet. 1987 Feb;26(2):377-83.
7599160	Quadros EV, Jacobsen DW: The dynamics of cobalamin utilization in L-1210 mouse leukemia cells: a model of cellular cobalamin metabolism. Biochim Biophys Acta. 1995 Jun 9;1244(2-3):395-403.
9587031	Ogier de Baulny H, Gerard M, Saudubray JM, Zittoun J: Remethylation defects: guidelines for clinical diagnosis and treatment. Eur J Pediatr. 1998 Apr;157 Suppl 2:S77-83.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
MTR

# Drug_Target_1_GenBank_ID_Gene:
U71285

# Drug_Target_1_GenBank_ID_Protein:
1923221

# Drug_Target_1_GeneCard_ID:
MTR

# Drug_Target_1_Gene_Name:
MTR

# Drug_Target_1_Gene_Sequence:
>3798 bp
ATGTCACCCGCGCTCCAAGACCTGTCGCAACCCGAAGGTCTGAAGAAAACCCTGCGGGAT
GAGATCAATGCCATTCTGCAGAAGAGGATTATGGTGCTGGATGGAGGGATGGGGACCATG
ATCCAGCGGGAGAAGCTAAACGAAGAACACTTCCGAGGTCAGGAATTTAAAGATCATGCC
AGGCCGCTGAAAGGCAACAATGACATTTTAAGTATAACTCAGCCTGATGTCATTTACCAA
ATCCATAAGGAATACTTGCTGGCTGGGGCAGATATCATTGAAACAAATACTTTTAGCAGC
ACTAGTATTGCCCAAGCTGACTATGGCCTTGAACACTTGGCCTACCGGATGAACATGTGC
TCTGCAGGAGTGGCCAGAAAAGCTGCCGAGGAGGTAACTCTCCAGACAGGAATTAAGAGG
TTTGTGGCAGGGGCTCTGGGTCCGACTAATAAGACACTCTCTGTGTCCCCATCTGTGGAA
AGGCCGGATTATAGGAACATCACATTTGATGAGCTTGTTGAAGCATACCAAGAGCAGGCC
AAAGGACTTCTGGATGGCGGGGTTGATATCTTACTCATTGAAACTATTTTTGATACTGCC
AATGCCAAGGCAGCCTTGTTTGCACTCCAAAATCTTTTTGAGGAGAAATATGCTCCCCGG
CCTATCTTTATTTCAGGGACGATCGTTGATAAAAGTGGGCGGACTCTTTCCGGACAGACA
GGAGAGGGATTTGTCATCAGCGTGTCTCATGGAGAACCACTCTGCATTGGATTAAATTGT
GCTTTGGGTGCAGCTGAGATGAGACCTTTTATTGAAATAATTGGAAAATGTACAACAGCC
TATGTCCTCTGTTATCCCAATGCAGGTCTTCCCAACACCTTTGGTGACTATGATGAAACG
CCTTCTATGATGGCCAAGCACCTAAAGGATTTTGCTATGGATGGCTTGGTCAATATAGTT
GGAGGATGCTGTGGGTCAACACCAGATCATATCAGGGAAATTGCTGAAGCTGTGAAAAAT
TGTAAGCCTAGAGTTCCACCTGCCACTGCTTTTGAAGGACATATGTTACTGTCTGGTCTA
GAGCCCTTCAGGATTGGACCGTACACCAACTTTGTTAACATTGGAGAGCGCTGTAATGTT
GCAGGATCAAGGAAGTTTGCTAAACTCATCATGGCAGGAAACTATGAAGAAGCCTTGTGT
GTTGCCAAAGTGCAGGTGGAAATGGGAGCCCAGGTGTTGGATGTCAACATGGATGATGGC
ATGCTAGATGGTCCAAGTGCAATGACCAGATTTTGCAACTTAATTGCTTCCGAGCCAGAC
ATCGCAAAGGTACCTTTGTGCATCGACTCCTCCAATTTTGCTGTGATTGAAGCTGGGTTA
AAGTGCTGCCAAGGGAAGTGCATTGTCAATAGCATTAGTCTGAAGGAAGGAGAGGACGAC
TTCTTGGAGAAGGCCAGGAAGATTAAAAAGTATGGAGCTGCTATGGTGGTCATGGCTTTT
GATGAAGAAGGACAGGCAACAGAAACAGACACAAAAATCAGAGTGTGCACCCGGGCCTAC
CATCTGCTTGTGAAAAAACTGGGCTTTAATCCAAATGACATTATTTTTGACCCTAATATC
CTAACCATTGGGACTGGAATGGAGGAACACAACTTGTATGCCATTAATTTTATCCATGCA
ACAAAAGTCATTAAAGAAACATTACCTGGAGCCAGAATAAGTGGAGGTCTTTCCAACTTG
TCCTTCTCCTTCCGAGGAATGGAAGCCATTCGAGAAGCAATGCATGGGGTTTTCCTTTAC
CATGCAATCAAGTCTGGCATGGACATGGGGATAGTGAATGCTGGAAACCTCCCTGTGTAT
GATGATATCCATAAGGAACTTCTGCAGCTCTGTGAAGATCTCATCTGGAATAAAGACCCT
GAGGCCACTGAGAAGCTCTTACGTTATGCCCAGACTCAAGGCACAGGAGGGAAGAAAGTC
ATTCAGACTGATGAGTGGAGAAATGGCCCTGTCGAAGAACGCCTTGAGTATGCCCTTGTG
AAGGGCATTGAAAAACATATTATTGAGGATACTGAGGAAGCCAGGTTAAACCAAAAAAAA
TATCCCCGACCTCTCAATATAATTGAAGGACCCCTGATGAATGGAATGAAAATTGTTGGT
GATCTTTTTGGAGCTGGAAAAATGTTTCTACCTCAGGTTATAAAGTCAGCCCGGGTTATG
AAGAAGGCTGTTGGCCACCTTATCCCTTTCATGGAAAAAGAAAGAGAAGAAACCAGAGTG
CTTAACGGCACAGTAGAAGAAGAGGACCCTTACCAGGGCACCATCGTGCTGGCCACTGTT
AAAGGCGACGTGCACGACATAGGCAAGAACATAGTTGGAGTAGTCCTTGGCTGCAATAAT
TTCCGAGTTATTGATTTAGGAGTCATGACTCCATGTGATAAGATACTGAAAGCTGCTCTT
GACCACAAAGCAGATATAATTGGCCTGTCAGGACTCATCACTCCTTCCCTGGATGAAATG
ATTTTTGTTGCCAAGGAAATGGAGAGATTAGCTATAAGGATTCCATTGTTGATTGGAGGA
GCAACCACTTCAAAAACCCACACAGCAGTTAAAATAGCTCCGAGATACAGTGCACCTGTA
ATCCATGTCCTGGACGCGTCCAAGAGTGTGGTGGTGTGTTCCCAGCTGTTAGATGAAAAT
CTAAAGGATGAATACTTTGAGGAAATCATGGAAGAATATGAAGATATTAGACAGGACCAT
TATGAGTCTCTCAAGGAGAGGAGATACTTACCCTTAAGTCAAGCCAGAAAAAGTGGTTTC
CAAATGGATTGGCTGTCTGAACCTCACCCAGTGAAGCCCACGTTTATTGGGACCCAGGTC
TTTGAAGACTATGACCTGCAGAAGCTGGTGGACTACATTGACTGGAAGCCTTTCTTTGAT
GTCTGGCAGCTCCGGGGCAAGTACCCGAATCGAGGCTTCCCCAAGATATTTAACGACAAA
ACAGTAGGTGGAGAGGCCAGGAAGGTCTACGATGATGCCCACAATATGCTGAACACACTG
ATTAGTCAAAAGAAACTCCGGGCCCGGGGTGTGGTTGGGTTCTGGCCAGCACAGAGTATC
CAAGACGACATTCACCTGTACGCAGAGGCTGCTGTGCCCCAGGCTGCAGAGCCCATAGCC
ACTTTCTATGGGTTAAGGCAACAGGCTGAGAAGGACTCTGCCAGCACGGAGCCATACTAC
TGCCTCTCAGACTTCATCGCTCCCTTGCATTCTGGCATCCGTGACTACCTGGGCCTGTTT
GCCGTTGCCTGCTTTGGGGTAGAAGAGCTGAGCAAGGCCTATGAGGATGATGGTGACGAC
TACAGCAGCATCATGGTCAAGGCGCTGGGGGACCGGCTGGCAGAGGCCTTTGCAGAAGAG
CTCCATGAAAGAGTTCGCCGAGAACTGTGGGCCTACTGTGGCAGTGAGCAGCTGGACGTC
GCAGACCTGCGAAGGTTGCGGTACAAGGGCATCCGCCCGGCTCCTGGCTACCCCAGCCAG
CCCGACCACACCGAGAAGCTCACCATGTGGAGACTCGCAGACATCGAGCAGTCTACAGGC
ATTAGGTTAACAGAATCATTAGCAATGGCACCTGCTTCAGCAGTCTCAGGCCTCTACTTC
TCCAATTTGAAGTCCAAATATTTTGCTGTGGGGAAGATTTCCAAGGATCAGGTTGAGGAT
TATGCATTGAGGAAGAACATATCTGTGGCTGAGGTTGAGAAATGGCTTGGACCCATTTTG
GGATATGATACAGACTAA

# Drug_Target_1_General_Function:
Amino acid transport and metabolism

# Drug_Target_1_General_References:
8968735	Li YN, Gulati S, Baker PJ, Brody LC, Banerjee R, Kruger WD: Cloning, mapping and RNA analysis of the human methionine synthase gene. Hum Mol Genet. 1996 Dec;5(12):1851-8.
8968736	Gulati S, Baker P, Li YN, Fowler B, Kruger W, Brody LC, Banerjee R: Defects in human methionine synthase in cblG patients. Hum Mol Genet. 1996 Dec;5(12):1859-65.
8968737	Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, Eydoux P, Rosenblatt DS, Rozen R, Gravel RA: Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet. 1996 Dec;5(12):1867-74.
9013615	Chen LH, Liu ML, Hwang HY, Chen LS, Korenberg J, Shane B: Human methionine synthase. cDNA cloning, gene localization, and expression. J Biol Chem. 1997 Feb 7;272(6):3628-34.

# Drug_Target_1_HGNC_ID:
HGNC:7468

# Drug_Target_1_HPRD_ID:
01136

# Drug_Target_1_ID:
809

# Drug_Target_1_Locus:
1q43

# Drug_Target_1_Molecular_Weight:
140529

# Drug_Target_1_Name:
Methionine synthase

# Drug_Target_1_Number_of_Residues:
1265

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Methotrexate Pathway	SMP00432

# Drug_Target_1_Pfam_Domain_Function:
PF00809	Pterin_bind
PF02310	B12-binding
PF02574	S-methyl_trans
PF02607	B12-binding_2
PF02965	Met_synt_B12

# Drug_Target_1_Protein_Sequence:
>Methionine synthase
MSPALQDLSQPEGLKKTLRDEINAILQKRIMVLDGGMGTMIQREKLNEEHFRGQEFKDHA
RPLKGNNDILSITQPDVIYQIHKEYLLAGADIIETNTFSSTSIAQADYGLEHLAYRMNMC
SAGVARKAAEEVTLQTGIKRFVAGALGPTNKTLSVSPSVERPDYRNITFDELVEAYQEQA
KGLLDGGVDILLIETIFDTANAKAALFALQNLFEEKYAPRPIFISGTIVDKSGRTLSGQT
GEGFVISVSHGEPLCIGLNCALGAAEMRPFIEIIGKCTTAYVLCYPNAGLPNTFGDYDET
PSMMAKHLKDFAMDGLVNIVGGCCGSTPDHIREIAEAVKNCKPRVPPATAFEGHMLLSGL
EPFRIGPYTNFVNIGERCNVAGSRKFAKLIMAGNYEEALCVAKVQVEMGAQVLDVNMDDG
MLDGPSAMTRFCNLIASEPDIAKVPLCIDSSNFAVIEAGLKCCQGKCIVNSISLKEGEDD
FLEKARKIKKYGAAMVVMAFDEEGQATETDTKIRVCTRAYHLLVKKLGFNPNDIIFDPNI
LTIGTGMEEHNLYAINFIHATKVIKETLPGARISGGLSNLSFSFRGMEAIREAMHGVFLY
HAIKSGMDMGIVNAGNLPVYDDIHKELLQLCEDLIWNKDPEATEKLLRYAQTQGTGGKKV
IQTDEWRNGPVEERLEYALVKGIEKHIIEDTEEARLNQKKYPRPLNIIEGPLMNGMKIVG
DLFGAGKMFLPQVIKSARVMKKAVGHLIPFMEKEREETRVLNGTVEEEDPYQGTIVLATV
KGDVHDIGKNIVGVVLGCNNFRVIDLGVMTPCDKILKAALDHKADIIGLSGLITPSLDEM
IFVAKEMERLAIRIPLLIGGATTSKTHTAVKIAPRYSAPVIHVLDASKSVVVCSQLLDEN
LKDEYFEEIMEEYEDIRQDHYESLKERRYLPLSQARKSGFQMDWLSEPHPVKPTFIGTQV
FEDYDLQKLVDYIDWKPFFDVWQLRGKYPNRGFPKIFNDKTVGGEARKVYDDAHNMLNTL
ISQKKLRARGVVGFWPAQSIQDDIHLYAEAAVPQAAEPIATFYGLRQQAEKDSASTEPYY
CLSDFIAPLHSGIRDYLGLFAVACFGVEELSKAYEDDGDDYSSIMVKALGDRLAEAFAEE
LHERVRRELWAYCGSEQLDVADLRRLRYKGIRPAPGYPSQPDHTEKLTMWRLADIEQSTG
IRLTESLAMAPASAVSGLYFSNLKSKYFAVGKISKDQVEDYALRKNISVAEVEKWLGPIL
GYDTD

# Drug_Target_1_Reaction:
5-methyltetrahydrofolate + L-homocysteine = tetrahydrofolate + L-methionine

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q99707

# Drug_Target_1_SwissProt_Name:
METH_HUMAN

# Drug_Target_1_Synonyms:
5-methyltetrahydrofolate-- homocysteine methyltransferase
EC 2.1.1.13
MS
Methionine synthase, vitamin-B12 dependent

# Drug_Target_1_Theoretical_pI:
5.27

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
11955068	Dayem LC, Carney JR, Santi DV, Pfeifer BA, Khosla C, Kealey JT: Metabolic engineering of a methylmalonyl-CoA mutase-epimerase pathway for complex polyketide biosynthesis in Escherichia coli. Biochemistry. 2002 Apr 23;41(16):5193-201.
18565	Tkachuck RD, Weinstein PP, Mueller JF: Metabolic fate of cyanocobalamin taken up by Spirometra mansonoides spargana. J Parasitol. 1977 Aug;63(4):694-700.
36882	Willard HF, Rosenberg LE: Inborn errors of cobalamin metabolism: effect of cobalamin supplementation in culture on methylmalonyl CoA mutase activity in normal and mutant human fibroblasts. Biochem Genet. 1979 Feb;17(1-2):57-75.
7599160	Quadros EV, Jacobsen DW: The dynamics of cobalamin utilization in L-1210 mouse leukemia cells: a model of cellular cobalamin metabolism. Biochim Biophys Acta. 1995 Jun 9;1244(2-3):395-403.
8741039	Mayatepek E, Hoffmann GF, Baumgartner R, Schulze A, Jakobs C, Trefz FK, Bremer HJ: Atypical vitamin B12-unresponsive methylmalonic aciduria in sibship with severe progressive encephalomyelopathy: a new genetic disease? Eur J Pediatr. 1996 May;155(5):398-403.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
MUT

# Drug_Target_2_GenBank_ID_Gene:
M65131

# Drug_Target_2_GenBank_ID_Protein:
187452

# Drug_Target_2_GeneCard_ID:
MUT

# Drug_Target_2_Gene_Name:
MUT

# Drug_Target_2_Gene_Sequence:
>2253 bp
ATGTTAAGAGCTAAGAATCAGCTTTTTTTACTTTCACCTCATTACCTGAGGCAGGTAAAA
GAATCATCAGGCTCCAGGCTCATACAGCAACGACTTCTACACCAGCAACAGCCCCTTCAC
CCAGAATGGGCTGCCCTGGCTAAAAAGCAGCTGAAAGGCAAAAACCCAGAAGACCTAATA
TGGCACACCCCGGAAGGGATCTCTATAAAACCCTTGTATTCCAAGAGAGATACTATGGAC
TTACCTGAAGAACTTCCAGGAGTGAAGCCATTCACACGTGGACCATATCCTACCATGTAT
ACCTTTAGGCCCTGGACCATCCGCCAGTATGCTGGTTTTAGTACTGTGGAAGAAAGCAAT
AAGTTCTATAAGGACAACATTAAGGCTGGTCAGCAGGGATTATCAGTTGCCTTTGATCTG
GCGACACATCGTGGCTATGATTCAGACAACCCTCGAGTTCGTGGTGATGTTGGAATGGCT
GGAGTTGCTATTGACACTGTGGAAGATACCAAAATTCTTTTTGATGGAATTCCTTTAGAA
AAAATGTCAGTTTCCATGACTATGAATGGAGCAGTTATTCCAGTTCTTGCAAATTTTATA
GTAACTGGAGAAGAACAAGGTGTACCTAAAGAGAAACTTACTGGTACCATCCAAAATGAT
ATACTAAAGGAATTTATGGTTCGAAATACATACATTTTTCCTCCAGAACCATCCATGAAA
ATTATTGCTGACATATTTGAATATACAGCAAAGCACATGCCAAAATTTAATTCAATTTCA
ATTAGTGGATACCATATGCAGGAAGCAGGGGCTGATGCCATTCTGGAGCTGGCCTATACT
TTAGCAGATGGATTGGAGTACTCTAGAACTGGACTCCAGGCTGGCCTGACAATTGATGAA
TTTGCACCAAGGTTGTCTTTCTTCTGGGGAATTGGAATGAATTTCTATATGGAAATAGCA
AAGATGAGAGCTGGTAGAAGACTCTGGGCTCACTTAATAGAGAAAATGTTTCAGCCTAAA
AACTCAAAATCTCTTCTTCTAAGAGCACACTGTCAGACATCTGGATGGTCACTTACTGAG
CAGGATCCCTACAATAATATTGTCCGTACTGCAATAGAAGCAATGGCAGCAGTATTTGGA
GGGACTCAGTCTTTGCACACAAATTCTTTTGATGAAGCTTTGGGTTTGCCAACTGTGAAA
AGTGCTCGAATTGCCAGGAACACACAAATCATCATTCAAGAAGAATCTGGGATTCCCAAA
GTGGCTGATCCTTGGGGAGGTTCTTACATGATGGAATGTCTCACAAATGATGTTTATGAT
GCTGCTTTAAAGCTCATTAATGAAATTGAAGAAATGGGTGGAATGGCCAAAGCTGTAGCT
GAGGGAATACCTAAACTTCGAATTGAAGAATGTGCTGCCCGAAGACAAGCTAGAATAGAT
TCTGGTTCTGAAGTAATTGTTGGAGTAAATAAGTACCAGTTGGAAAAAGAAGACGCTGTA
GAAGTTCTGGCAATTGATAATACTTCAGTGCGAAACAGGCAGATTGAAAAACTTAAGAAG
ATCAAATCCAGCAGGGATCAAGCTTTGGCTGAACATTGTCTTGCTGCACTAACCGAATGT
GCTGCTAGCGGAGATGGAAATATCCTGGCTCTTGCAGTGGATGCATCTCGGGCAAGATGT
ACAGTGGGAGAAATCACAGATGCCCTGAAAAAGGTATTTGGTGAACATAAAGCGAATGAT
CGAATGGTGAGTGGAGCATATCGCCAGGAATTTGGAGAAAGTAAAGAGATAACATCTGCT
ATCAAGAGGGTTCATAAATTCATGGAACGTGAAGGTCGCAGACCTCGTCTTCTTGTAGCA
AAAATGGGACAAGATGGCCATGACAGAGGAGCAAAAGTTATTGCTACAGGATTTGCTGAT
CTTGGTTTTGATGTGGACATAGGCCCTCTTTTCCAGACTCCTCGTGAAGTGGCCCAGCAG
GCTGTGGATGCGGATGTGCATGCTGTGGGCGTAAGCACCCTCGCTGCTGGTCATAAAACC
CTAGTTCCTGAACTCATCAAAGAACTTAACTCCCTTGGACGGCCAGATATTCTTGTCATG
TGTGGAGGGGTGATACCACCTCAGGATTATGAATTTCTGTTTGAAGTTGGTGTTTCCAAT
GTATTTGGTCCTGGGACTCGAATTCCAAAGGCTGCCGTTCAGGTGCTTGATGATATTGAG
AAGTGTTTGGAAAAGAAGCAGCAATCTGTATAA

# Drug_Target_2_General_Function:
Lipid transport and metabolism

# Drug_Target_2_General_References:
1346616	Crane AM, Jansen R, Andrews ER, Ledley FD: Cloning and expression of a mutant methylmalonyl coenzyme A mutase with altered cobalamin affinity that causes mut- methylmalonic aciduria. J Clin Invest. 1992 Feb;89(2):385-91.
1351030	Crane AM, Martin LS, Valle D, Ledley FD: Phenotype of disease in three patients with identical mutations in methylmalonyl CoA mutase. Hum Genet. 1992 May;89(3):259-64.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
1670635	Raff ML, Crane AM, Jansen R, Ledley FD, Rosenblatt DS: Genetic characterization of a MUT locus mutation discriminating heterogeneity in mut0 and mut- methylmalonic aciduria by interallelic complementation. J Clin Invest. 1991 Jan;87(1):203-7.
1977311	Jansen R, Ledley FD: Heterozygous mutations at the mut locus in fibroblasts with mut0 methylmalonic acidemia identified by polymerase-chain-reaction cDNA cloning. Am J Hum Genet. 1990 Nov;47(5):808-14.
1980486	Nham SU, Wilkemeyer MF, Ledley FD: Structure of the human methylmalonyl-CoA mutase (MUT) locus. Genomics. 1990 Dec;8(4):710-6.
2567699	Jansen R, Kalousek F, Fenton WA, Rosenberg LE, Ledley FD: Cloning of full-length methylmalonyl-CoA mutase from a cDNA library using the polymerase chain reaction. Genomics. 1989 Feb;4(2):198-205.
7909321	Qureshi AA, Crane AM, Matiaszuk NV, Rezvani I, Ledley FD, Rosenblatt DS: Cloning and expression of mutations demonstrating intragenic complementation in mut0 methylmalonic aciduria. J Clin Invest. 1994 Apr;93(4):1812-9.
7912889	Crane AM, Ledley FD: Clustering of mutations in methylmalonyl CoA mutase associated with mut- methylmalonic acidemia. Am J Hum Genet. 1994 Jul;55(1):42-50.
8990001	Ledley FD, Rosenblatt DS: Mutations in mut methylmalonic acidemia: clinical and enzymatic correlations. Hum Mutat. 1997;9(1):1-6.
9452100	Adjalla CE, Hosack AR, Matiaszuk NV, Rosenblatt DS: A common mutation among blacks with mut- methylmalonic aciduria. Hum Mutat. 1998;Suppl 1:S248-50.
9554742	Adjalla CE, Hosack AR, Gilfix BM, Lamothe E, Sun S, Chan A, Evans S, Matiaszuk NV, Rosenblatt DS: Seven novel mutations in mut methylmalonic aciduria. Hum Mutat. 1998;11(4):270-4.

# Drug_Target_2_HGNC_ID:
HGNC:7526

# Drug_Target_2_HPRD_ID:
02014

# Drug_Target_2_ID:
854

# Drug_Target_2_Locus:
6p21

# Drug_Target_2_Molecular_Weight:
83121

# Drug_Target_2_Name:
Methylmalonyl-CoA mutase, mitochondrial

# Drug_Target_2_Number_of_Residues:
750

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01642	MM_CoA_mutase
PF02310	B12-binding

# Drug_Target_2_Protein_Sequence:
>Methylmalonyl-CoA mutase, mitochondrial precursor
MLRAKNQLFLLSPHYLRQVKESSGSRLIQQRLLHQQQPLHPEWAALAKKQLKGKNPEDLI
WHTPEGISIKPLYSKRDTMDLPEELPGVKPFTRGPYPTMYTFRPWTIRQYAGFSTVEESN
KFYKDNIKAGQQGLSVAFDLATHRGYDSDNPRVRGDVGMAGVAIDTVEDTKILFDGIPLE
KMSVSMTMNGAVIPVLANFIVTGEEQGVPKEKLTGTIQNDILKEFMVRNTYIFPPEPSMK
IIADIFEYTAKHMPKFNSISISGYHMQEAGADAILELAYTLADGLEYSRTGLQAGLTIDE
FAPRLSFFWGIGMNFYMEIAKMRAGRRLWAHLIEKMFQPKNSKSLLLRAHCQTSGWSLTE
QDPYNNIVRTAIEAMAAVFGGTQSLHTNSFDEALGLPTVKSARIARNTQIIIQEESGIPK
VADPWGGSYMMECLTNDVYDAALKLINEIEEMGGMAKAVAEGIPKLRIEECAARRQARID
SGSEVIVGVNKYQLEKEDAVEVLAIDNTSVRNRQIEKLKKIKSSRDQALAERCLAALTEC
AASGDGNILALAVDASRARCTVGEITDALKKVFGEHKANDRMVSGAYRQEFGESKEITSA
IKRVHKFMEREGRRPRLLVAKMGQDGHDRGAKVIATGFADLGFDVDIGPLFQTPREVAQQ
AVDADVHAVGVSTLAAGHKTLVPELIKELNSLGRPDILVMCGGVIPPQDYEFLFEVGVSN
VFGPGTRIPKAAVQVLDDIEKCLEKKQQSV

# Drug_Target_2_Reaction:
(R)-methylmalonyl-CoA = succinyl-CoA

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Involved in the degradation of several amino acids, odd- chain fatty acids and cholesterol via propionyl-CoA to the tricarboxylic acid cycle. MCM has different functions in other species

# Drug_Target_2_SwissProt_ID:
P22033

# Drug_Target_2_SwissProt_Name:
MUTA_HUMAN

# Drug_Target_2_Synonyms:
EC 5.4.99.2
MCM
Methylmalonyl-CoA isomerase
Methylmalonyl-CoA mutase, mitochondrial precursor

# Drug_Target_2_Theoretical_pI:
6.92

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Isoform B, isoform C:Cytoplasm. Isoform A:Mitochondrion (Probable)

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
MTRR

# Drug_Target_3_GenBank_ID_Gene:
AF121213

# Drug_Target_3_GenBank_ID_Protein:
6572540

# Drug_Target_3_GeneCard_ID:
MTRR

# Drug_Target_3_Gene_Name:
MTRR

# Drug_Target_3_Gene_Sequence:
>2178 bp
ATGGGCGCTGCGTCAGTGCGCGCTGGCGCAAGGTTGGTGGAAGTCGCGTTGTGCAGTTTC
ACTGTTACATGCCTTGAAGTGATGAGGAGGTTTCTGTTACTATATGCTACACAGCAGGGA
CAGGCAAAGGCCATCGCAGAAGAAATGTGTGAGCAAGCTGTGGTACATGGATTTTCTGCA
GATCTTCACTGTATTAGTGAATCCGATAAGTATGACCTAAAAACCGAAACAGCTCCTCTT
GTTGTTGTGGTTTCTACCACGGGCACCGGAGACCCACCCGACACAGCCCGCAAGTTTGTT
AAGGAAATACAGAACCAAACACTGCCGGTTGATTTCTTTGCTCACCTGCGGTATGGGTTA
CTGGGTCTCGGTGATTCAGAATACACCTACTTTTGCAATGGGGGGAAGATAATTGATAAA
CGACTTCAAGAGCTTGGAGCCCGGCATTTCTATGACACTGGACATGCAGATGACTGTGTA
GGTTTAGAACTTGTGGTTGAGCCGTGGATTGCTGGACTCTGGCCAGCCCTCAGAAAGCAT
TTTAGGTCAAGCAGAGGACAAGAGGAGATAAGTGGCGCACTCCCGGTGGCATCACCTGCA
TCCTTGAGGACAGACCTTGTGAAGTCAGAGCTGCTACACATTGAATCTCAAGTCGAGCTT
CTGAGATTCGATGATTCAGGAAGAAAGGATTCTGAGGTTTTGAAGCAAAATGCAGTGAAC
AGCAACCAATCCAATGTTGTAATTGAAGACTTTGAGTCCTCACTTACCCGTTCGGTACCC
CCACTCTCACAAGCCTCTCTGAATATTCCTGGTTTACCCCCAGAATATTTACAGGTACAT
CTGCAGGAGTCTCTTGGCCAGGAGGAAAGCCAAGTATCTGTGACTTCAGCAGATCCAGTT
TTTCAAGTGCCAATTTCAAAGGCAGTTCAACTTACTACGAATGATGCCATAAAAACCACT
CTGCTGGTAGAATTGGACATTTCAAATACAGACTTTTCCTATCAGCCTGGAGATGCCTTC
AGCGTGATCTGCCCTAACAGTGATTCTGAGGTACAAAGCCTACTCCAAAGACTGCAGCTT
GAAGATAAAAGAGAGCACTGCGTCCTTTTGAAAATAAAGGCAGACACAAAGAAGAAAGGA
GCTACCTTACCCCAGCATATACCTGCGGGATGTTCTCTCCAGTTCATTTTTACCTGGTGT
CTTGAAATCCGAGCAATTCCTAAAAAGGCATTTTTGCGAGCCCTTGTGGACTATACCAGT
GACAGTGCTGAAAAGCGCAGGCTACAGGAGCTGTGCAGTAAACAAGGGGCAGCCGATTAT
AGCCGCTTTGTACGAGATGCCTGTGCCTGCTTGTTGGATCTCCTCCTCGCTTTCCCTTCT
TGCCAGCCACCACTCAGTCTCCTGCTCGAACATCTTCCTAAACTTCAACCCAGACCATAT
TCGTGTGCAAGCTCAAGTTTATTTCACCCAGGAAAGCTCCATTTTGTCTTCAACATTGTG
GAATTTCTGTCTACTGCCACAACAGAGGTTCTGCGGAAGGGAGTATGTACAGGCTGGCTG
GCCTTGTTGGTTGCTTCAGTTCTTCAGCCAAACATACATGCATCCCATGAAGACAGCGGG
AAAGCCCTGGCTCCTAAGATATCCATCTCTCCTCGAACAACAAATTCTTTCCACTTACCA
GATGACCCCTCAATCCCCATCATAATGGTGGGTCCAGGAACCGGCATAGCCCCGTTTATT
GGGTTCCTACAACATAGAGAGAAACTCCAAGAACAACACCCAGATGGAAATTTTGGAGCA
ATGTGGTTGTTTTTTGGCTGCAGGCATAAGGATAGGGATTATCTATTCAGAAAAGAGCTC
AGACATTTCCTTAAGCATGGGATCTTAACTCATCTAAAGGTTTCCTTCTCAAGAGATGCT
CCTGTTGGGGAGGAGGAAGCCCCAGCAAAGTATGTACAAGACAACATCCAGCTTCATGGC
CAGCAGGTGGCGAGAATCCTCCTCCAGGAGAACGGCCATATTTATGTGTGTGGAGATGCA
AAGAATATGGCCAAGGATGTACATGATGCCCTTGTGCAAATAATAAGCAAAGAGGTTGGA
GTTGAAAAACTAGAAGCAATGAAAACCCTGGCCACTTTAAAAGAAGAAAAACGCTACCTT
CAGGATATTTGGTCATAA

# Drug_Target_3_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_3_General_References:
10444342	Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, Gravel RA, Rozen R: A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab. 1999 Aug;67(4):317-23.
10484769	Wilson A, Leclerc D, Rosenblatt DS, Gravel RA: Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism. Hum Mol Genet. 1999 Oct;8(11):2009-16.
10564814	Leclerc D, Odievre M, Wu Q, Wilson A, Huizenga JJ, Rozen R, Scherer SW, Gravel RA: Molecular cloning, expression and physical mapping of the human methionine synthase reductase gene. Gene. 1999 Nov 15;240(1):75-88.
9501215	Leclerc D, Wilson A, Dumas R, Gafuik C, Song D, Watkins D, Heng HH, Rommens JM, Scherer SW, Rosenblatt DS, Gravel RA: Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3059-64.

# Drug_Target_3_HGNC_ID:
HGNC:7473

# Drug_Target_3_HPRD_ID:
03979

# Drug_Target_3_ID:
840

# Drug_Target_3_Locus:
5p15.3-p15.2

# Drug_Target_3_Molecular_Weight:
80437

# Drug_Target_3_Name:
Methionine synthase reductase, mitochondrial

# Drug_Target_3_Number_of_Residues:
725

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00258	Flavodoxin_1
PF00667	FAD_binding_1

# Drug_Target_3_Protein_Sequence:
>Methionine synthase reductase, mitochondrial precursor
MGAASVRAGARLVEVALCSFTVTCLEVMRRFLLLYATQQGQAKAIAEEICEQAVVHGFSA
DLHCISESDKYDLKTETAPLVVVVSTTGTGDPPDTARKFVKEIQNQTLPVDFFAHLRYGL
LGLGDSEYTYFCNGGKIIDKRLQELGARHFYDTGHADDCVGLELVVEPWIAGLWPALRKH
FRSSRGQEEISGALPVASPASLRTDLVKSELLHIESQVELLRFDDSGRKDSEVLKQNAVN
SNQSNVVIEDFESSLTRSVPPLSQASLNIPGLPPEYLQVHLQESLGQEESQVSVTSADPV
FQVPISKAVQLTTNDAIKTTLLVELDISNTDFSYQPGDAFSVICPNSDSEVQSLLQRLQL
EDKREHCVLLKIKADTKKKGATLPQHIPAGCSLQFIFTWCLEIRAIPKKAFLRALVDYTS
DSAEKRRLQELCSKQGAADYSRFVRDACACLLDLLLAFPSCQPPLSLLLEHLPKLQPRPY
SCASSSLFHPGKLHFVFNIVEFLSTATTEVLRKGVCTGWLALLVASVLQPNIHASHEDSG
KALAPKISISPRTTNSFHLPDDPSIPIIMVGPGTGIAPFIGFLQHREKLQEQHPDGNFGA
MWLFFGCRHKDRDYLFRKELRHFLKHGILTHLKVSFSRDAPVGEEEAPAKYVQDNIQLHG
QQVARILLQENGHIYVCGDAKNMAKDVHDALVQIISKEVGVEKLEAMKTLATLKEEKRYL
QDIWS

# Drug_Target_3_Reaction:
2 [methionine synthase]-methylcob(I)alamin + 2 S-adenosylhomocysteine + NADP+ = 2 [methionine synthase]-cob(I)alamin + NADPH + H+ + 2 S-adenosyl-L-methionine

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Involved in the reductive regeneration of cob(I)alamin cofactor required for the maintenance of methionine synthase in a functional state

# Drug_Target_3_SwissProt_ID:
Q9UBK8

# Drug_Target_3_SwissProt_Name:
MTRR_HUMAN

# Drug_Target_3_Synonyms:
EC 1.16.1.8
MSR
Methionine synthase reductase, mitochondrial precursor

# Drug_Target_3_Theoretical_pI:
6.47

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Mitochondrion (Probable)

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
20301409	Manoli I, Venditti CP: Methylmalonic Acidemia

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
MMAA

# Drug_Target_4_GenBank_ID_Gene:
AF524846

# Drug_Target_4_GenBank_ID_Protein:
26006421

# Drug_Target_4_GeneCard_ID:
MMAA

# Drug_Target_4_Gene_Name:
MMAA

# Drug_Target_4_Gene_Sequence:
>1257 bp
ATGCCCATGCTGCTACCACATCCTCACCAGCATTTCCTAAAAGGCCTTTTAAGAGCACCT
TTCCGATGTTACCACTTCATCTTTCACTCAAGTACTCATCTCGGATCAGGAATCCCATGT
GCTCAGCCGTTTAATTCTCTTGGACTCCATTGTACAAAGTGGATGCTGCTGTCAGATGGC
TTAAAGAGAAAATTATGTGTACAAACAACCTTAAAGGACCACACAGAAGGACTTTCTGAT
AAAGAGCAAAGATTTGTGGATAAACTTTATACTGGTTTAATCCAAGGGCAAAGGGCCTGT
TTAGCAGAGGCCATAACTCTTGTAGAATCAACTCACAGCAGGAAAAAGGAGTTAGCCCAG
GTGCTTCTTCAGAAAGTATTACTTTACCACAGAGAACAAGAACAATCAAATAAAGGAAAA
CCACTAGCATTTCGAGTAGGATTGTCTGGGCCCCCTGGTGCTGGAAAATCAACATTTATA
GAATATTTTGGAAAAATGCTTACTGAGAGAGGGCACAAATTATCTGTGCTAGCTGTGGAC
CCTTCTTCTTGTACTAGTGGTGGATCACTCTTAGGTGATAAAACCCGAATGACTGAGTTA
TCAAGAGATATGAATGCATACATCAGGCCATCTCCTACTAGAGGAACTTTAGGAGGCGTG
ACAAGGACCACAAATGAAGCTATTCTGTTGTGTGAAGGAGCGGGATATGACATAATTCTT
ATTGAAACCGTTGGTGTGGGTCAGTCGGAGTTTGCTGTTGCTGACATGGTTGACATGTTT
GTTTTACTACTGCCACCAGCAGGAGGAGATGAGCTGCAGGGTATCAAAAGGGGTATAATC
GAGATGGCAGATCTGGTAGCTGTAACTAAATCTGATGGAGACTTGATTGTGCCAGCTCGA
AGGATACAAGCGGAATATGTGAGTGCACTGAAATTACTCCGCAAACGTTCACAAGTCTGG
AAACCAAAGGTAATTCGTATTTCTGCCCGAAGTGGAGAGGGGATCTCTGAAATGTGGGAT
AAAATGAAAGATTTCCAGGACCTAATGCTTGCCAGTGGGGAGCTGACTGCCAAACGACGG
AAGCAACAGAAAGTTTGGATGTGGAATCTCATTCAGGAAAGTGTGTTAGAGCATTTCAGG
ACCCACCCCACAGTCCGGGAACAGATTCCACTTCTGGAACAAAAGGTTCTCATTGGGGCC
CTGTCCCCAGGACTAGCAGCAGACTTCTTGTTAAAAGCTTTTAAAAGCAGAGACTAA

# Drug_Target_4_General_Function:
Amino acid transport and metabolism

# Drug_Target_4_General_References:
12438653	Dobson CM, Wai T, Leclerc D, Wilson A, Wu X, Dore C, Hudson T, Rosenblatt DS, Gravel RA: Identification of the gene responsible for the cblA complementation group of vitamin B12-responsive methylmalonic acidemia based on analysis of prokaryotic gene arrangements. Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15554-9. Epub 2002 Nov 15.

# Drug_Target_4_HGNC_ID:
HGNC:18871

# Drug_Target_4_HPRD_ID:
07394

# Drug_Target_4_ID:
354

# Drug_Target_4_Locus:
4q31.22

# Drug_Target_4_Molecular_Weight:
46539

# Drug_Target_4_Name:
Methylmalonic aciduria type A protein, mitochondrial

# Drug_Target_4_Number_of_Residues:
418

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF03308	ArgK

# Drug_Target_4_Protein_Sequence:
>Methylmalonic aciduria type A protein, mitochondrial precursor
MPMLLPHPHQHFLKGLLRAPFRCYHFIFHSSTHLGSGIPCAQPFNSLGLHCTKWMLLSDG
LKRKLCVQTTLKDHTEGLSDKEQRFVDKLYTGLIQGQRACLAEAITLVESTHSRKKELAQ
VLLQKVLLYHREQEQSNKGKPLAFRVGLSGPPGAGKSTFIEYFGKMLTERGHKLSVLAVD
PSSCTSGGSLLGDKTRMTELSRDMNAYIRPSPTRGTLGGVTRTTNEAILLCEGAGYDIIL
IETVGVGQSEFAVADMVDMFVLLLPPAGGDELQGIKRGIIEMADLVAVTKSDGDLIVPAR
RIQAEYVSALKLLRKRSQVWKPKVIRISARSGEGISEMWDKMKDFQDLMLASGELTAKRR
KQQKVWMWNLIQESVLEHFRTHPTVREQIPLLEQKVLIGALSPGLAADFLLKAFKSRD

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
May be involved in the transport of cobalamin (Cbl) into mitochondria for the final steps of adenosylcobalamin (AdoCbl) synthesis

# Drug_Target_4_SwissProt_ID:
Q8IVH4

# Drug_Target_4_SwissProt_Name:
MMAA_HUMAN

# Drug_Target_4_Synonyms:
Methylmalonic aciduria type A protein, mitochondrial precursor

# Drug_Target_4_Theoretical_pI:
9.83

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Secreted protein

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
6726060	Rothenberg SP, Marcoullis GP, Schwarz S, Lader E: Measurement of cyanocobalamin in serum by a specific radioimmunoassay. J Lab Clin Med. 1984 Jun;103(6):959-72.
844253	MacDonald CM, Farquharson J, Bessent RG, Adams JF: The forms of vitamin B12 on the transcobalamins. Clin Sci Mol Med. 1977 Feb;52(2):215-8.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
TCN1

# Drug_Target_5_GenBank_ID_Gene:
J05068

# Drug_Target_5_GenBank_ID_Protein:
307479

# Drug_Target_5_GeneCard_ID:
TCN1

# Drug_Target_5_Gene_Name:
TCN1

# Drug_Target_5_Gene_Sequence:
>1302 bp
ATGAGACAGTCACACCAGCTGCCCCTAGTGGGGCTCTTACTGTTTTCTTTTATTCCAAGC
CAACTATGCGAGATTTGTGAGGTAAGTGAAGAAAACTACATCCGCCTAAAACCTCTGTTG
AATACAATGATCCAGTCAAACTATAACAGGGGAACCAGCGCTGTCAATGTTGTGTTGTCC
CTCAAACTTGTTGGAATCCAGATCCAAACCCTGATGCAAAAGATGATCCAACAAATCAAA
TACAATGTGAAAAGCAGATTGTCAGATGTAAGCTCGGGAGAGCTTGCCTTGATTATACTG
GCTTTGGGAGTATGTCGTAACGCTGAGGAAAACTTAATATATGATTACCACCTGACTGAC
AAGCTAGAAAATAAATTCCAAGCAGAAATTGAAAATATGGAAGCACACAATGGCACTCCC
CTGACTAACTACTACCAGCTCAGCCTGGACGTTTTGGCCTTGTGTCTGTTCAATGGGAAC
TACTCAACCGCCGAAGTTGTCAACCACTTCACTCCTGAAAATAAAAACTATTATTTTGGT
AGCCAGTTCTCAGTAGATACTGGTGCAATGGCTGTCCTGGCTCTGACCTGTGTGAAGAAG
AGTCTAATAAATGGGCAGATCAAAGCAGATGAAGGCAGTTTAAAGAACATCAGTATTTAT
ACAAAGTCACTGGTAGAAAAGATTCTGTCTGAGAAAAAAGAAAATGGTCTCATTGGAAAC
ACATTTAGCACAGGAGAAGCCATGCAGGCCCTCTTTGTATCATCAGACTATTATAATGAA
AATGACTGGAATTGCCAACAAACTCTGAATACAGTGCTCACGGAAATTTCTCAAGGAGCA
TTCAGTAATCCAAACGCTGCAGCCCAGGTCTTACCTGCCCTGATGGGAAAGACCTTCTTG
GATATTAACAAAGACTCTTCTTGCGTCTCTGCTTCAGGTAACTTCAACATCTCCGCTGAT
GAGCCTATAACTGTGACACCTCCTGACTCACAATCATATATCTCCGTCAATTACTCTGTG
AGAATCAATGAAACATATTTCACCAATGTCACTGTGCTAAATGGTTCTGTCTTCCTCAGT
GTGATGGAGAAAGCCCAGAAAATGAATGATACTATATTTGGTTTCACAATGGAGGAGCGC
TCATGGGGGCCCTATATCACCTGTATTCAGGGCCTATGTGCCAACAATAATGACAGAACC
TACTGGGAACTTCTGAGTGGAGGCGAACCACTGAGCCAAGGAGCTGGTAGTTACGTTGTC
CGCAATGGAGAAAACTTGGAGGTTCGCTGGAGCAAATACTAA

# Drug_Target_5_General_Function:
Involved in cobalamin binding

# Drug_Target_5_General_References:
2777761	Johnston J, Bollekens J, Allen RH, Berliner N: Structure of the cDNA encoding transcobalamin I, a neutrophil granule protein. J Biol Chem. 1989 Sep 25;264(27):15754-7.

# Drug_Target_5_HGNC_ID:
HGNC:11652

# Drug_Target_5_HPRD_ID:
01795

# Drug_Target_5_ID:
265

# Drug_Target_5_Locus:
11q11-q12

# Drug_Target_5_Molecular_Weight:
48195

# Drug_Target_5_Name:
Transcobalamin-1

# Drug_Target_5_Number_of_Residues:
433

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF01122	Cobalamin_bind

# Drug_Target_5_Protein_Sequence:
>Transcobalamin-1 precursor
MRQSHQLPLVGLLLFSFIPSQLCEICEVSEENYIRLKPLLNTMIQSNYNRGTSAVNVVLS
LKLVGIQIQTLMQKMIQQIKYNVKSRLSDVSSGELALIILALGVCRNAEENLIYDYHLTD
KLENKFQAEIENMEAHNGTPLTNYYQLSLDVLALCLFNGNYSTAEVVNHFTPENKNYYFG
SQFSVDTGAMAVLALTCVKKSLINGQIKADEGSLKNISIYTKSLVEKILSEKKENGLIGN
TFSTGEAMQALFVSSDYYNENDWNCQQTLNTVLTEISQGAFSNPNAAAQVLPALMGKTFL
DINKDSSCVSASGNFNISADEPITVTPPDSQSYISVNYSVRINETYFTNVTVLNGSVFLS
VMEKAQKMNDTIFGFTMEERSWGPYITCIQGLCANNNDRTYWELLSGGEPLSQGAGSYVV
RNGENLEVRWSKY

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
1-23

# Drug_Target_5_Specific_Function:
Vitamin B12-binding protein. Transports cobalamin into cells

# Drug_Target_5_SwissProt_ID:
P20061

# Drug_Target_5_SwissProt_Name:
TCO1_HUMAN

# Drug_Target_5_Synonyms:
TC I
TCI
Transcobalamin I
Transcobalamin-1 precursor

# Drug_Target_5_Theoretical_pI:
4.68

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Membrane
single-pass type I membrane protein (Potential)

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
14585166	Seetharam B, Yammani RR: Cobalamin transport proteins and their cell-surface receptors. Expert Rev Mol Med. 2003 Jun 13;5(18):1-18.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
AMN

# Drug_Target_6_GenBank_ID_Gene:
AF328788

# Drug_Target_6_GenBank_ID_Protein:
13507259

# Drug_Target_6_GeneCard_ID:
AMN

# Drug_Target_6_Gene_Name:
AMN

# Drug_Target_6_Gene_Sequence:
>1362 bp
ATGGGCGTCCTGGGCCGGGTCCTGCTGTGGCTGCAGCTCTGCGCACTGACCCAGGCGGTC
TCCAAACTCTGGGTCCCCAACACGGACTTCGACGTCGCAGCCAACTGGAGCCAGAACCGG
ACCCCGTGCGCCGGCGGCGCCGTTGAGTTCCCGGCGGACAAGATGGTGTCAGTCCTGGTG
CAAGAAGGTCACGCCGTCTCAGACATGCTCCTGCCGCTGGATGGGGAACTCGTCCTGGCT
TCAGGAGCCGGATTCGGCGTCTCAGACGTGGGCTCGCACCTGGACTGTGGCGCGGGCGAA
CCTGCCGTCTTCCGCGACTCTGACCGCTTCTCCTGGCATGACCCGCACCTGTGGCGCTCT
GGGGACGAGGCACCTGGCCTCTTCTTCGTGGACGCCGAGCGCGTGCCCTGCCGCCACGAC
GACGTCTTCTTTCCGCCTAGTGCCTCCTTCCGCGTGGGGCTCGGCCCTGGCGCTAGCCCC
GTGCGTGTCCGCAGCATCTCGGCTCTGGGCCGGACGTTCACGCGCGACGAGGACCTGGCT
GTTTTCCTGGCGTCCCGCGCGGGCCGCCTACGCTTCCACGGGCCGGGCGCGCTGAGCGTG
GGCCCCGAGGACTGCGCGGACCCGTCGGGCTGCGTCTGCGGCAACGCGGAGGCGCAGCCG
TGGATCTGCGCGGCCCTGCTCCAGCCCCTGGGCGGCCGCTGTCCCCAGGCCGCCTGCCAC
TTTGCCCTCCGGCCCCAGGGGCAGTGCTGTGACCTCTGTGGAGCCGTTGTGTTGCTGACC
CACGGCCCCGCATTTGACCTGGAGCGGTACCGGGCGCGGATACTGGACACCTTCCTGGGT
CTGCCTCAGTACCACGGGCTGCAGGTGGCCGTGTCCAAGGTGCCACGCTCGTCCCGGCTC
CGTGAGGCCGATACGGAGATCCAGGTGGTGCTGGTGGAGAATGGGCCCGAGACAGGCGGA
GCGGGGCGGCTGGCCCGGGCCCTCCTGGCGGACGTCGCCGAGAACGGCGAGGCCCTCGGC
GTCCTGGAGGCGACCATGCGGGAGTCGGGCGCACACGTCTGGGGCAGCTCCGCGGCTGGG
CTGGCGGGCGGCGTGGCGGCTGCCGTGCTGCTGGCGCTGCTGGTCCTGCTGGTGGCGCCG
CCGCTGCTGCGCCGCGCGGGGAGGCTCAGGTGGAGGAGGCACGAGGCGGCGGCCCCGGCT
GGAGCGCCCCTCGGCTTCCGCAACCCGGTGTTCGACGTGACGGCCTCCGAGGAGCTGCCC
CTGCCGCGGCGGCTCAGCCTGGTTCCGAAGGCGGCCGCAGACAGCACCAGCCACAGTTAC
TTCGTCAACCCTCTGTTCGCCGGGGCCGAGGCCGAGGCCTGA

# Drug_Target_6_General_Function:
Not Available

# Drug_Target_6_General_References:
11279523	Kalantry S, Manning S, Haub O, Tomihara-Newberger C, Lee HG, Fangman J, Disteche CM, Manova K, Lacy E: The amnionless gene, essential for mouse gastrulation, encodes a visceral-endoderm-specific protein with an extracellular cysteine-rich domain. Nat Genet. 2001 Apr;27(4):412-6.
12590260	Tanner SM, Aminoff M, Wright FA, Liyanarachchi S, Kuronen M, Saarinen A, Massika O, Mandel H, Broch H, de la Chapelle A: Amnionless, essential for mouse gastrulation, is mutated in recessive hereditary megaloblastic anemia. Nat Genet. 2003 Mar;33(3):426-9. Epub 2003 Feb 18.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.

# Drug_Target_6_HGNC_ID:
HGNC:14604

# Drug_Target_6_HPRD_ID:
09314

# Drug_Target_6_ID:
376

# Drug_Target_6_Locus:
14q32.3

# Drug_Target_6_Molecular_Weight:
47815

# Drug_Target_6_Name:
Amnionless protein

# Drug_Target_6_Number_of_Residues:
453

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
Not Available

# Drug_Target_6_Protein_Sequence:
>Amnionless protein precursor
MGVLGRVLLWLQLCALTQAVSKLWVPNTDFDVAANWSQNRTPCAGGAVEFPADKMVSVLV
QEGHAVSDMLLPLDGELVLASGAGFGVSDVGSHLDCGAGEPAVFRDSDRFSWHDPHLWRS
GDEAPGLFFVDAERVPCRHDDVFFPPSASFRVGLGPGASPVRVRSISALGRTFTRDEDLA
VFLASRAGRLRFHGPGALSVGPEDCADPSGCVCGNAEAQPWICAALLQPLGGRCPQAACH
FALRPQGQCCDLCGAVVLLTHGPAFDLERYRARILDTFLGLPQYHGLQVAVSKVPRSSRL
READTEIQVVLVENGPETGGAGRLARALLADVAENGEALGVLEATMRESGAHVWGSSAAG
LAGGVAAAVLLALLVLLVAPPLLRRAGRLRWRRHEAAAPAGAPLGFRNPVFDVTASEELP
LPRRLSLVPKAAADSTSHSYFVNPLFAGAEAEA

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
1-19

# Drug_Target_6_Specific_Function:
Necessary for efficient absorption of vitamin B12. May direct the production of trunk mesoderm during development by modulating a bone morphogenetic protein (BMP) signaling pathway in the underlying visceral endoderm

# Drug_Target_6_SwissProt_ID:
Q9BXJ7

# Drug_Target_6_SwissProt_Name:
AMNLS_HUMAN

# Drug_Target_6_Synonyms:
Amnionless protein precursor

# Drug_Target_6_Theoretical_pI:
6.09

# Drug_Target_6_Transmembrane_Regions:
358-378

# Drug_Target_7_Cellular_Location:
Endosome
endosomal membrane
lysosomal membrane
peripheral
peripheral membrane protein. Lysosome

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
14585166	Seetharam B, Yammani RR: Cobalamin transport proteins and their cell-surface receptors. Expert Rev Mol Med. 2003 Jun 13;5(18):1-18.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
CUBN

# Drug_Target_7_GenBank_ID_Gene:
AF034611

# Drug_Target_7_GenBank_ID_Protein:
3929529

# Drug_Target_7_GeneCard_ID:
CUBN

# Drug_Target_7_Gene_Name:
CUBN

# Drug_Target_7_Gene_Sequence:
>10872 bp
ATGATGAACATGTCTTTACCTTTTCTTTGGAGTTTGCTTACCTTATTAATATTTGCTGAA
GTAAATGGCGAACGTGGAGAACTTGAGCTGCAGAGACAAAAAAGAAGCATCAATCTCCAA
CAGCCTCGAATGGCTACAGAGAGAGGAAATTTGGTGTTTCTTACGGGGTCTGCTCAAAAC
ATTGAGTTTAGAACCGGATCCCTGGGAAAAATTAAATTAAATGATGAAGATCTCAGTGAG
TGTTTACATCAGATCCAGAAAAACAAAGAAGATATTATAGAGTTAAAAGGGAGCGCAATT
GGTCTGCCTCAAAATATATCTAGTCAAATCTATCAGCTTAATTCCAAGCTGGTGGATCTT
GAGAGAAAATTCCAAGGCTTGCAGCAGACTGTTGACAAAAAGGTTTGCAGCAGCAATCCT
TGCCAGAATGGTGGGAACTGCCTCAATCTGCATGATTCCTTTTTTTGTATCTGTCCCCCA
CAGTGGAAGGGTCCTCTCTGCTCAGCTGATGTTAACGAATGTGAGATTTACTCAGGAACA
CCCTTGAGCTGCCAGAATGGAGGCACATGTGTTAATACAATGGGAAGTTACAGTTGTCAC
TGCCCACCTGAGACGTACGGACCCCAGTGTGCATCCAAATATGACGACTGTGAAGGGGGT
TCTGTGGCACGCTGTGTCCATGGCATCTGTGAGGATTTAATGCGAGAGCAAGCTGGAGAG
CCCAAGTACAGCTGCGTCTGTGATGCTGGGTGGATGTCTTCACCCAACAGCCCTGCCTGC
ACGCTGGACAGAGACGAGTGCAGCTTCCAGCCCGGGCCTTGCTCCACACTTGTGCAGTGT
TTCAACACTCAAGGCTCTTTCTACTGTGGGGCCTGTCCAACAGGCTGGCAAGGCAATGGA
TATATTTGCGAAGATATCAATGAATGTGAGATAAATAATGGCGGCTGTTCTGTGGCTCCA
CCCGTTGAGTGTGTGAATACACCTGGGTCTTCCCACTGCCAGGCCTGTCCACCAGGGTAC
CAGGGTGACGGAAGAGTGTGCACACTCACAGACATCTGCTCAGTCAGTAATGGAGGCTGC
CACCCAGATGCCTCATGCTCCTCAACTCTAGGTTCCTTACCTCTCTGCACGTGTCTCCCG
GGTTATACTGGAAATGGTTATGGGCCAAATGGATGTGTGCAGCTCAGTAATATTTGCCTA
AGTCACCCCTGTCTAAATGGACAATGCATCGACACTGTCTCTGGTTATTTTTGTAAGTGT
GACTCAGGTTGGACAGGTGTCAACTGTACAGAAAACATCAATGAGTGTTTGAGCAACCCC
TGTTTGAATGGAGGAACTTGTGTTGATGGCGTTGATTCTTTCAGTTGTGAATGCACACGT
CTCTGGACTGGAGCTCTCTGTCAGGTTCCTCAGCAAGTTTGTGGAGAGTCCCTCTCAGGA
ATAAATGGAAGCTTCAGCTACAGGAGCCCGGATGTTGGTTATGTTCATGATGTTAACTGC
TTCTGGGTTATCAAAACTGAAATGGGAAAGGTCCTGCGTATCACTTTCACTTTTTTCCGG
TTAGAATCCATGGACAACTGTCCACACGAGTTTCTTCAGGTTTATGATGGAGATTCCTCT
TCTGCTTTTCAACTTGGAAGATTTTGTGGCTCCAGCCTCCCTCATGAACTCCTCAGCAGT
GACAATGCTCTCTATTTTCATCTCTATTCTGAACATTTAAGAAATGGGAGAGGCTTTACA
GTAAGATGGGAAACACAGCAACCAGAGTGTGGAGGTATCCTGACTGGTCCTTACGGTTCT
ATTAAGTCTCCGGGGTATCCTGGAAACTATCCCCCAGGAAGAGATTGTGTCTGGATTGTT
GTAACTAGTCCTGACCTCCTGGTAACATTTACTTTTGGGACCTTGAGCCTCGAGCACCAT
GATGACTGCAACAAAGATTACCTTGAGATTCGAGATGGTCCTTTGTATCAGGACCCCCTT
CTTGGGAAGTTCTGCACCACTTTCTCTGTCCCACCGCTCCAGACTACTGGCCCCTTTGCC
AGAATTCACTTCCATTCAGACTCCCAGATTAGTGACCAAGGCTTCCATATCACCTACTTA
ACATCACCTTCGGATCTGCGTTGTGGTGGGAACTACACGGACCCAGAGGGTGAACTCTTC
TTGCCTGAGTTGTCTGGGCCTTTCACTCACACCAGGCAATGCGTCTATATGATGAAGCAG
CCCCAGGGAGAACAAATACAAATCAACTTCACCCACGTGGAGCTGCAATGCCAGAGTGAC
AGTTCTCAGAATTACATTGAGGTTCGAGATGGTGAAACCTTACTTGGAAAAGTCTGTGGC
AACGGAACCATCTCTCACATTAAATCCATTACTAATAGTGTCTGGATCAGGTTTAAAATA
GATGCTTCTGTTGAAAAAGCTAGTTTCAGAGCTGTTTATCAAGTCGCTTGCGGGGATGAA
TTAACTGGAGAAGGGGTCATTCGCTCGCCTTTTTTTCCTAACGTGTATCCTGGAGAAAGA
ACCTGTAGGTGGACCATCCACCAGCCCCAAAGCCAAGTCATTCTCCTCAACTTCACTGTC
TTTGAAATTGGAAGTTCTGCCCACTGTGAAACAGATTATGTTGAGATTGGTAGCAGTTCC
ATTTTGGGTTCTCCTGAAAATAAAAAGTATTGCGGTACAGACATACCTTCATTTATAACA
TCTGTGTACAATTTTCTTTATGTCACATTCGTGAAAAGTTCTTCTACTGAAAACCATGGT
TTCATGGCTAAGTTCAGTGCTGAGGATTTGGCATGTGGAGAAATTCTTACAGAATCAACA
GGGACCATTCAAAGTCCTGGCCATCCAAATGTCTACCCCCACGGTATCAACTGTACTTGG
CATATATTAGTCCAACCTAATCACCTGATTCATTTAATGTTCGAAACATTTCATCTGGAG
TTTCATTACAATTGCACAAACGACTACTTGGAAGTTTATGACACCGACTCTGAGACATCC
CTTGGAAGATACTGTGGAAAGTCGATCCCGCCATCTCTCACAAGCAGTGGTAACTCATTG
ATGCTGGTGTTTGTGACTGACTCCGACCTCGCTTATGAAGGCTTCTTAATAAACTATGAA
GCAATCAGTGCAGCAACAGCATGTTTGCAAGACTACACAGATGATTTGGGGACATTCACT
TCTCCAAACTTCCCCAATAATTATCCCAACAACTGGGAATGCATTTATCGGATCACAGTG
AGAACTGGCCAACTGATTGCAGTGCACTTCACAAACTTCTCCTTGGAGGAAGCCATTGGA
AACTATTATACAGATTTTCTGGAAATCAGAGATGGAGGCTATGAAAAATCACCATTGCTG
GGAATATTCTATGGCTCAAATCTACCCCCAACAATCATCTCTCATAGTAACAAACTATGG
TTAAAATTTAAGAGTGACCAAATAGACACAAGGTCTGGATTCTCAGCTTACTGGGATGGG
TCATCAACAGGTTGCGGGGGTAATCTCACCACTTCAAGCGGTACGTTCATATCTCCCAAC
TACCCGATGCCCTATTACCACAGCTCTGAATGCTACTGGTGGTTGAAATCTAGCCACGGC
AGCGCATTTGAACTGGAATTCAAAGACTTTCACTTGGAGCATCATCCAAACTGCACTTTA
GATTACCTGGCTGTATATGATGGCCCAAGTAGCAACTCTCATCTGCTAACTCAGCTTTGT
GGGGATGAGAAACCCCCTCTTATTCGTTCTAGTGGAGACAGCATGTTTATAAAACTGAGG
ACAGATGAAGGTCAGCAAGGACGTGGCTTCAAGGCTGAATACCGGCAGACATGTGAGAAT
GTGGTAATAGTCAATCAAACCTATGGCATCTTAGAGAGTATAGGGTATCCGAATCCTTAT
TCTGAAAATCAGCATTGCAACTGGACCATCCGGGCAACAACAGGCAACACTGTGAACTAC
ACATTTTTAGCATTTGACTTGGAACATCACATAAACTGCTCCACAGATTATTTAGAGCTC
TATGATGGACCACGGCAGATGGGACGCTACTGTGGAGTAGACCTGCCCCCTCCAGGGAGT
ACTACAAGCTCCAAGCTTCAAGTGCTGCTCCTTACAGATGGGGTTGGCCGCCGTGAGAAA
GGATTTCAGATGCAGTGGTTTGTTTACGGTTGTGGTGGAGAGCTGTCTGGGGCCACAGGC
TCCTTCAGCAGCCCCGGGTTCCCCAACAGGTATCCACCAAACAAGGAGTGTATCTGGTAC
ATTAGGACGGACCCCGGGAGTAGCATTCAGCTCACCATCCATGACTTCGATGTGGAGTAT
CATTCAAGGTGCAACTTTGATGTCTTGGAGATCTATGGAGGCCCCGATTTCCACTCTCCC
AGAATAGCCCAACTGTGTACCCAGAGATCACCTGAGAACCCCATGCAGGTCTCCAGCACT
GGAAATGAGCTAGCAATTCGATTCAAGACCGACTTGTCCATAAATGGGAGAGGCTTCAAT
GCGTCATGGCAAGCAGTCACTGGAGGTTGTGGTGGGATTTTCCAGGCTCCCAGTGGAGAG
ATTCATTCTCCAAATTACCCCAGTCCTTATAGGAGCAACACAGACTGTTCTTGGGTCATT
CGGGTTGACAGATATCATCGTGTTCTCTTGAACTTCACTGACTTTGATCTTGAACCACAA
GACTCTTGTATTATGGCATACGATGGCTTAAGCTCCACAATGTCCCGCCTTGCCAGGACG
TGTGGAAGGGAGCAGCTGGCTAACCCCATCGTCTCCTCAGGAAACAGCCTCTTCTTGAGA
TTTCAGTCTGGCCCTTCCAGACAGAACAGAGGCTTCCGAGCTCAATTCAGGCAAGCCTGC
GGAGGCCACATCCTCACCAGCTCATTTGATACTGTTTCCTCTCCACGGTTCCCTGCCAAT
TATCCAAACAATCAGAACTGCAGCTGGATCATTCAAGCGCAACCTCCATTAAATCATATC
ACCCTCTCTTTTACCCACTTTGAACTTGAAAGAAGCACAACGTGTGCACGTGACTTTGTA
GAAATTTTGGATGGCGGCCACGAAGACGCGCCCCTCCGAGGCCGTTACTGTGGCACCGAC
ATGCCCCATCCTATCACATCCTTCAGCAGCGCCCTGACGCTGAGATTCGTCTCTGATTCT
AGCATCAGTGCTGGGGGTTTCCACACCACGGTCACCGCATCAGTGTCGGCTTGTGGTGGA
ACGTTCTACATGGCTGAAGGCATCTTCAACAGCCCTGGCTACCCAGACATTTATCCCCCT
AATGTGGAATGTGTCTGGAACATCATCAGTTCCCCTGGCAACCGGCTCCAGCTGTCTTTT
ATATCTTTCCAGTTGGAAGACTCTCAGGACTGCAGCAGAGATTTTGTGGAGATCCGTGAA
GGAAATGCCACGGGTCACTTGGTGGGACGATACTGTGGAAACTCCTTCCCTCTCAATTAT
TCTTCCATCGTTGGACATACCCTGTGGGTCAGATTTATCTCAGATGGTTCTGGCAGCGGC
ACGGGCTTCCAGGCCACATTTATGAAGATATTTGGCAATGATAATATTGTGGGAACTCAT
GGGAAAGTCGCCTCTCCTTTCTGGCCTGAAAACTACCCACATAACTCCAATTACCAATGG
ACAGTAAATGTGAATGCATCTCACGTTGTCCATGGTAGAATCTTGGAGATGGACATAGAA
GAAATACAAAACTGCTATTATGACAAATTAAGGATCTATGATGGGCCTAGCATTCACGCC
CGCCTAATTGGAGCTTACTGTGGTACCCAGACTGAATCTTTCAGCTCCACTGGAAATTCT
TTGACATTTCATTTTTACTCCGACTCTTCAATCTCGGGGAAGGGATTCCTTCTGGAGTGG
TTTGCAGTGGATGCACCTGATGGTGTTTTACCTACCATTGCTCCAGGTGCTTGTGGTGGC
TTCCTGAGGACGGGAGATGCACCCGTGTTTCTCTTCTCCCCGGGCTGGCCTGACAGTTAC
AGTAATAGAGTGGACTGTACGTGGCTCATCCAGGCTCCCGACTCTACCGTGGAACTCAAC
ATTCTTTCCCTGGACATTGAATCTCACCGAACGTGTGCCTATGATAGCCTTGTGATACGA
GATGGAGATAATAACTTGGCCCAGCAGCTAGCAGTTCTCTGTGGCAGAGAGATCCCTGGG
CCCATCCGGTCTACTGGAGAGTACATGTTCATCCGCTTCACCTCGGACTCCAGTGTAACC
AGGGCAGGCTTCAATGCATCCTTTCACAAGAGCTGCGGTGGATATTTGCATGCAGACAGA
GGGATCATCACGTCCCCCAAGTATCCAGAGACTTACCCATCCAACCTCAACTGTTCTTGG
CACGTCCTGGTCCAAAGTGGCCTGACCATTGCTGTCCATTTTGAACAGCCTTTCCAGATT
CCAAATGGAGATTCTTCTTGCAACCAGGGGGATTACTTGGTGCTAAGAAATGGTCCTGAT
ATCTATTCTCCACCCTTGGGACCCCCTGGAGGAAATGGTCATTTTTGTGGCAGTCATGCT
TCATCAACTCTGTTCACCTCGGATAATCAAATGTTTGTTCAGTTTATTTCTGATCACAGT
AATGAAGGGCAAGGATTTAAAATCAAATATGAGGCAAAGAGTTTAGCCTGTGGGGGCAAC
GTCTACATCCATGATGCTGATTCTGCTGGGTATGTGACCTCCCCCAACCACCCTCATAAT
TATCCCCCGCACGCTGATTGCATTTGGATCTTAGCGGCTCCACCGGAAACACGCATACAG
CTGCAATTTGAAGATCGATTCGATATTGAAGTAACACCCAACTGTACTTCCAACTACCTT
GAGTTGCGGGATGGAGTGGATTCGGATGCACCAATACTTTCCAAATTTTGTGGGACATCT
TTGCCCAGCAGTCAGTGGTCCTCAGGAGAGGTTATGTATTTGAGATTTCGATCTGACAAC
AGCCCCACACATGTGGGATTCAAGGCCAAGTATTCTATAGCTCAGTGTGGGGGAAGAGTA
CCAGGGCAAAGTGGTGTTGTTGAAAGCATTGGACATCCAACACTTCCATACAGAGACAAC
TTATTCTGTGAGTGGCATCTCCAGGGGCTCTCTGGACACTATCTCACCATCTCTTTTGAA
GACTTTAACCTTCAGAATTCTTCTGGCTGTGAAAAAGACTTCGTGGAGATCTGGGACAAT
CATACCTCTGGAAACATCTTGGGCAGATACTGTGGAAACACCATTCCTGACAGCATAGAC
ACTTCTAGCAATACTGCTGTGGTCAGGTTTGTCACAGACGGCTCTGTGACTGCCTCAGGA
TTCAGACTGCGATTTGAATCCAGTATGGAAGAGTGTGGTGGGGATCTTCAGGGCTCTATT
GGAACATTTACTTCTCCCAACTACCCGAACCCAAATCCTCATGGCCGGATCTGCGAGTGG
AGAATCACTGCCCCGGAGGGAAGGCGGATCACCCTAATGTTTAACAACCTGAGGCTGGCC
ACGCATCCGTCCTGCAACAATGAGCATGTGATAGTATTCAATGGCATTAGAAGTAACTCA
CCCCAGCTAGAGAAACTGTGTAGTAGTGTGAATGTAAGCAATGAGATTAAATCTTCAGGA
AACACAATGAAAGTCATTTTTTTCACGGATGGATCCAGGCCATATGGCGGCTTCACTGCT
TCCTATACCTCCAGTGAAGATGCAGTGTGTGGTGGGTCTCTTCCAAATACTCCTGAAGGA
AACTTTACTTCTCCTGGCTATGACGGAGTCAGGAATTACTCAAGAAACCTGAACTGCGAA
TGGACTCTCAGCAATCCAAATCAGGGAAATTCATCCATTTCCATTCACTTTGAAGATTTT
TACCTAGAAAGTCACCAAGACTGTCAATTTGATGTCCTCGAGTTTCGAGTGGGTGATGCT
GATGGGCCCCTGATGTGGAGACTTTGTGGTCCTTCAAAGCCTACATTGCCATTGGTTATA
CCTTATTCTCAGGTATGGATTCACTTTGTCACCAACGAACGTGTAGAACACATTGGATTC
CATGCAAAGTATTCCTTTACAGATTGTGGCGGAATACAGATAGGTGACAGTGGAGTGATC
ACAAGCCCCAACTATCCAAATGCTTATGACAGCCTGACCCACTGCTCTTGGCTGTTGGAG
GCCCCACAAGGGCACACCATCACTCTCACATTTAGTGACTTTGATATTGAACCCCATACA
ACTTGTGCTTGGGACTCTGTCACTGTCAGGAATGGTGGGTCCCCTGAATCACCCATCATA
GGACAATACTGTGGAAATTCAAACCCCAGGACAATACAGTCAGGTTCCAATCAGCTGGTC
GTGACTTTTAACTCAGACCATTCATTGCAAGGTGGTGGATTTTATGCTACGTGGAACACA
CAAACTTTAGGTTGTGGTGGAATATTTCATTCTGATAATGGTACAATCAGATCCCCTCAC
TGGCCTCAGAATTTTCCCGAAAACAGCAGATGTTCCTGGACGGCCATTACTCACAAAAGT
AAACACTTGGAGATCAGCTTTGACAACAACTTCCTAATCCCCAGCGGTGATGGACAATGT
CAGAATAGCTTCGTGAAGGTGTGGGCAGGAACTGAGGAGGTGGACAAAGCCCTGCTAGCC
ACTGGCTGTGGGAACGTGGCTCCGGGTCCCGTTATCACACCAAGTAACACATTCACTGCC
GTCTTCCAGTCTCAGGAGGCACCAGCTCAGGGCTTCTCCGCGTCCTTTGTTAGCCGATGT
GGAAGTAATTTCACTGGCCCTTCAGGTTACATCATTTCTCCAAATTACCCAAAACAATAT
GACAACAACATGAATTGCACCTATGTCATAGAGGCTAATCCTCTGTCAGTGGTCCTCTTG
ACTTTTGTGTCCTTCCACTTAGAAGCTCGTTCCGCTGTGACGGGAAGCTGTGTCAACGAT
GGCGTGCACATTATCAGAGGTTACAGCGTCATGTCCACCCCATTTGCTACTGTGTGTGGG
GATGAGATGCCAGCTCCCCTCACCATCGCTGGGCCGGTTCTGCTTAACTTCTACTCCAAC
GAGCAAATCACAGACTTCGGATTCAAGTTTTCCTATAGGATAATCTCCTGTGGTGGTGTG
TTCAATTTCTCTTCTGGAATCATCACAAGTCCTGCCTATTCATACGCAGACTACCCAAAT
GATATGCACTGTCTGTATACCATCACCGTTAGTGACGACAAGGTGATCGAGCTCAAGTTC
AGTGATTTTGATGTGGTTCCCTCCACCTCCTGCTCCCATGACTACCTGGCAATTTACGAT
GGTGCCAATACCAGCGATCCCCTTCTTGGCAAATTCTGCGGTTCCAAGCGCCCACCAAAT
GTGAAGAGCAGCAATAATAGTATGCTCCTGGTGTTCAAGACAGATTCATTTCAGACAGCA
AAAGGCTGGAAGATGTCTTTCCGGCAGACATTGGGGCCTCAGCAAGGATGTGGTGGTTAT
CTGACAGGCTCGAATAATACCTTTGCCTCTCCTGATTCTGATTCGAATGGAATGTATGAC
AAGAATTTAAACTGTGTATGGATCATAATTGCACCTGTAAACAAAGTAATTCACCTCACC
TTCAATACATTTGCTCTGGAGGCAGCAAGTACTAGGCAAAGATGCCTTTATGATTATGTA
AAGTTATATGATGGGGATAGTGAAAATGCGAACTTGGCTGGAACGTTTTGTGGTTCCACA
GTACCTGCTCCTTTTATCTCTTCTGGTAACTTCCTTACGGTTCAATTCATCAGTGACTTA
ACATTAGAGAGGGAAGGATTTAATGCTACATACACCATCATGGACATGCCTTGTGGTGGA
ACGTACAATGCAACTTGGACCCCACAAAATATTTCATCACCCAATTCATCAGACCCAGAT
GTCCCATTTTCCATCTGTACTTGGGTCATTGATTCCCCTCCGCATCAGCAGGTCAAGATA
ACTGTGTGGGCATTACAGCTGACCTCGCAAGACTGCACGCAGAATTACTTACAGCTTCAG
GACTCACCGCAGGGTCACGGAAATTCAAGATTTCAGTTCTGTGGCAGAAATGCTTCGGCT
GTGCCAGTGTTTTATTCTTCTATGAGTACTGCAATGGTCATTTTCAAATCTGGAGTTGTA
AACAGAAACTCTAGAATGAGTTTCACCTATCAGATTGCAGATTGCAACAGAGACTATCAC
AAGGCATTTGGCAACCTGAGAAGCCCTGGATGGCCAGATAACTACGACAATGACAAGGAT
TGCACCGTTACTCTCACAGCCCCCCAGAACCACACCATTTCCCTCTTTTTTCATTCACTT
GGCATCGAGAACTCAGTTGAATGCAGAAACGATTTCTTGGAGGTGAGAAATGGAAGTAAC
AGCAATTCACCATTACTGGGCAAGTACTGTGGAACTCTGCTGCCAAACCCTGTCTTCTCT
CAAAATAATGAACTATACCTACGATTTAAGAGTGATAGTGTAACTTCTGATCGTGGATAT
GAAATCATCTGGACTTCATCACCCTCTGGATGTGGTGGAACTCTTTATGGAGACAGAGGC
TCATTCACCAGCCCCGGCTATCCAGGCACATACCCAAACAACACGTACTGCGAGTGGGTC
CTTGTTGCTCCTGCTGGAAGGCTTGTCACCATCAACTTCTACTTCATCAGCATTGACGAT
CCAGGAGACTGTGTCCAGAACTATCTCACACTCTATGATGGGCCCAACGCCAGCTCTCCA
TCCTCTGGACCATACTGCGGAGGCGACACCAGCATAGCTCCCTTCGTGGCTTCCTCAAAT
CAGGTCTTCATAAAATTTCATGCTGATTATGCACGGCGTCCATCCGCATTCCGATTAACT
TGGGACAGCTAA

# Drug_Target_7_General_Function:
Involved in calcium ion binding

# Drug_Target_7_General_References:
9572993	Kozyraki R, Kristiansen M, Silahtaroglu A, Hansen C, Jacobsen C, Tommerup N, Verroust PJ, Moestrup SK: The human intrinsic factor-vitamin B12 receptor, cubilin: molecular characterization and chromosomal mapping of the gene to 10p within the autosomal recessive megaloblastic anemia (MGA1) region. Blood. 1998 May 15;91(10):3593-600.

# Drug_Target_7_HGNC_ID:
HGNC:2548

# Drug_Target_7_HPRD_ID:
04296

# Drug_Target_7_ID:
1224

# Drug_Target_7_Locus:
10p12.31

# Drug_Target_7_Molecular_Weight:
398729

# Drug_Target_7_Name:
Cubilin

# Drug_Target_7_Number_of_Residues:
3623

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00008	EGF
PF00431	CUB
PF07645	EGF_CA

# Drug_Target_7_Protein_Sequence:
>Cubilin precursor
MMNMSLPFLWSLLTLLIFAEVNGEAGELELQRQKRSINLQQPRMATERGNLVFLTGSAQN
IEFRTGSLGKIKLNDEDLSECLHQIQKNKEDIIELKGSAIGLPQNISSQIYQLNSKLVDL
ERKFQGLQQTVDKKVCSSNPCQNGGTCLNLHDSFFCICPPQWKGPLCSADVNECEIYSGT
PLSCQNGGTCVNTMGSYSCHCPPETYGPQCASKYDDCEGGSVARCVHGICEDLMREQAGE
PKYSCVCDAGWMSSPNSPACTLDRDECSFQPGPCSTLVQCFNTQGSFYCGACPTGWQGNG
YICEDINECEINNGGCSVAPPVECVNTPGSSHCQACPPGYQGDGRVCTLTDICSVSNGGC
HPDASCSSTLGSLPLCTCLPGYTGNGYGPNGCVQLSNICLSHPCLNGQCIDTVSGYFCKC
DSGWTGVNCTENINECLSNPCLNGGTCVDGVDSFSCECTRLWTGALCQVPQQVCGESLSG
INGSFSYRSPDVGYVHDVNCFWVIKTEMGKVLRITFTFFRLESMDNCPHEFLQVYDGDSS
SAFQLGRFCGSSLPHELLSSDNALYFHLYSEHLRNGRGFTVRWETQQPECGGILTGPYGS
IKSPGYPGNYPPGRDCVWIVVTSPDLLVTFTFGTLSLEHHDDCNKDYLEIRDGPLYQDPL
LGKFCTTFSVPPLQTTGPFARIHFHSDSQISDQGFHITYLTSPSDLRCGGNYTDPEGELF
LPELSGPFTHTRQCVYMMKQPQGEQIQINFTHVELQCQSDSSQNYIEVRDGETLLGKVCG
NGTISHIKSITNSVWIRFKIDASVEKASFRAVYQVACGDELTGEGVIRSPFFPNVYPGER
TCRWTIHQPQSQVILLNFTVFEIGSSAHCETDYVEIGSSSILGSPENKKYCGTDIPSFIT
SVYNFLYVTFVKSSSTENHGFMAKFSAEDLACGEILTESTGTIQSPGHPNVYPHGINCTW
HILVQPNHLIHLMFETFHLEFHYNCTNDYLEVYDTDSETSLGRYCGKSIPPSLTSSGNSL
MLVFVTDSDLAYEGFLINYEAISAATACLQDYTDDLGTFTSPNFPNNYPNNWECIYRITV
RTGQLIAVHFTNFSLEEAIGNYYTDFLEIRDGGYEKSPLLGIFYGSNLPPTIISHSNKLW
LKFKSDQIDTRSGFSAYWDGSSTGCGGNLTTSSGTFISPNYPMPYYHSSECYWWLKSSHG
SAFELEFKDFHLEHHPNCTLDYLAVYDGPSSNSHLLTQLCGDEKPPLIRSSGDSMFIKLR
TDEGQQGRGFKAEYRQTCENVVIVNQTYGILESIGYPNPYSENQHCNWTIRATTGNTVNY
TFLAFDLEHHINCSTDYLELYDGPRQMGRYCGVDLPPPGSTTSSKLQVLLLTDGVGRREK
GFQMQWFVYGCGGELSGATGSFSSPGFPNRYPPNKECIWYIRTDPGSSIQLTIHDFDVEY
HSRCNFDVLEIYGGPDFHSPRIAQLCTQRSPENPMQVSSTGNELAIRFKTDLSINGRGFN
ASWQAVTGGCGGIFQAPSGEIHSPNYPSPYRSNTDCSWVIRVDRNHRVLLNFTDFDLESQ
DSCIMAYDGLSSTMSRLARTCGREQLANPIVSSGNSLFLRFQSGPSRQNRGFRAQFRQAC
GGHILTSSFDTVSSPRFPANYPNNQNCSWIIQAQPPLNHITLSFTHFELERSTTCARDFV
EILDGGHEDAPLRGRYCGTDMPHPITSFSSALTLRFVSDSSISAGGFHTTVTASVSACGG
TFYMAEGIFNSPGYPDIYPPNVECVWNIVSSPGNRLQLSFISFQLEDSQDCSRDFVEIRE
GNATGHLVGRYCGNSFPLNYSSIVGHTLWVRFISDGSGSGTGFQATFMKIFGNDNIVGTH
GKVASPFWPENYPHNSNYQWTVNVNASHVVHGRILEMDIEEIQNCYYDKLRIYDGPSIHA
RLIGAYCGTQTESFSSTGNSLTFHFYSDSSISGKGFLLEWFAVDAPDGVLPTIAPGACGG
FLRTGDAPVFLFSPGWPDSYSNRVDCTWLIQAPDSTVELNILSLDIESHRTCAYDSLVIR
DGDNNLAQQLAVLCGREIPGPIRSTGEYMFIRFTSDSSVTRAGFNASFHKSCGGYLHADR
GIITSPKYPETYPSNLNCSWHVLVQSGLTIAVHFEQPFQIPNGDSSCNQGDYLVLRNGPD
IYSPPLGPPGGNGHFCGSHASSTLFTSDNQMFVQFISDHSNEGQGFKIKYEAKSLACGGN
VYIHDADSAGYVTSPNHPHNYPPHADCIWILAAPPETRIQLQFEDRFDIEVTPNCTSNYL
ELRDGVDSDAPILSKFCGTSLPSSQWSSGEVMYLRFRSDNSPTHVGFKAKYSIAQCGGRV
PGQSGVVESIGHPTLPYRDNLFCEWHLQGLSGHYLTISFEDFNLQNSSGCEKDFVEIWDN
HTSGNILGRYCGNTIPDSIDTSSNTAVVRFVTDGSVTASGFRLRFESSMEECGGDLQGSI
GTFTSPNYPNPNPHGRICEWRITAPEGRRITLMFNNLRLATHPSCNNEHVIVFNGIRSNS
PQLEKLCSSVNVSNEIKSSGNTMKVIFFTDGSRPYGGFTASYTSSEDAVCGGSLPNTPEG
NFTSPGYDGVRNYSRNLNCEWTLSNPNQGNSSISIHFEDFYLESHQDCQFDVLEFRVGDA
DGPLMWRLCGPSKPTLPLVIPYSQVWIHFVTNERVEHIGFHAKYSFTDCGGIQIGDSGVI
TSPNYPNAYDSLTHCSSLLEAPQGHTITLTFSDFDIEPHTTCAWDSVTVRNGGSPESPII
GQYCGNSNPRTIQSGSNQLVVTFNSDHSLQGGGFYATWNTQTLGCGGIFHSDNGTIRSPH
WPQNFPENSRCSWTAITHKSKHLEISFDNNFLIPSGDGQCQNSFVKVWAGTEEVDKALLA
TGCGNVAPGPVITPSNTFTAVFQSQEAPAQGFSASFVSRCGSNFTGPSGYIISPNYPKQY
DNNMNCTYVIEANPLSVVLLTFVSFHLEARSAVTGSCVNDGVHIIRGYSVMSTPFATVCG
DEMPAPLTIAGPVLLNFYSNEQITDFGFKFSYRIISCGGVFNFSSGIITSPAYSYADYPN
DMHCLYTITVSDDKVIELKFSDFDVVPSTSCSHDYLAIYDGANTSDPLLGKFCGSKRPPN
VKSSNNSMLLVFKTDSFQTAKGWKMSFRQTLGPQQGCGGYLTGSNNTFASPDSDSNGMYD
KNLNCVWIIIAPVNKVIHLTFNTFALEAASTRQRCLYDYVKLYDGDSENANLAGTFCGST
VPAPFISSGNFLTVQFISDLTLEREGFNATYTIMDMPCGGTYNATWTPQNISSPNSSDPD
VPFSICTWVIDSPPHQQVKITVWALQLTSQDCTQNYLQLQDSPQGHGNSRFQFCGRNASA
VPVFYSSMSTAMVIFKSGVVNRNSRMSFTYQIADCNRDYHKAFGNLRSPGWPDNYDNDKD
CTVTLTAPQNHTISLFFHSLGIENSVECRNDFLEVRNGSNSNSPLLGKYCGTLLPNPVFS
QNNELYLRFKSDSVTSDRGYEIIWTSSPSGCGGTLYGDRGSFTSPGYPGTYPNNTYCEWV
LVAPAGRLVTINFYFISIDDPGDCVQNYLTLYDGPNASSPSSGPYCGGDTSIAPFVASSN
QVFIKFHADYARRPSAFRLTWDS

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
1-23

# Drug_Target_7_Specific_Function:
Cotransporter which plays a role in lipoprotein, vitamin and iron metabolism, by facilitating their uptake. Binds to ALB, MB, Kappa and lambda-light chains, TF, hemoglobin, GC, SCGB1A1, APOA1, high density lipoprotein, and the GIF-cobalamin complex. The binding of all ligands required calcium. Serves as important transporter in several absorptive epithelia, including intestine, renal proximal tubules and embryonic yolk sac. Interaction with LRP2 mediates its trafficking throughout vesicles and facilitates the uptake of specific ligands like GC, hemoglobin, ALB, TF and SCGB1A1. Interaction with AMN controls its trafficking to the plasma membrane and facilitates endocytosis of ligands. May play an important role in the development of the peri-implantation embryo through internalization of APOA1 and cholesterol. Binds to LGALS3 at the maternal-fetal interface

# Drug_Target_7_SwissProt_ID:
O60494

# Drug_Target_7_SwissProt_Name:
CUBN_HUMAN

# Drug_Target_7_Synonyms:
460 kDa receptor
Cubilin precursor
Intestinal intrinsic factor receptor
Intrinsic factor-cobalamin receptor
Intrinsic factor-vitamin B12 receptor

# Drug_Target_7_Theoretical_pI:
5.00

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Mitochondrion (Probable)

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
MMAB

# Drug_Target_8_GenBank_ID_Gene:
AF550404

# Drug_Target_8_GenBank_ID_Protein:
26284726

# Drug_Target_8_GeneCard_ID:
MMAB

# Drug_Target_8_Gene_Name:
MMAB

# Drug_Target_8_Gene_Sequence:
>753 bp
ATGGCTGTGTGCGGCCTGGGGAGCCGTCTTGGCCTGGGGAGCCGTCTTGGCCTGCGCGGG
TGCTTCGGCGCCGCCAGGCTCCTGTATCCCCGTTTCCAGAGCCGCGGCCCTCAGGGCGTG
GAAGACGGGGACAGGCCACAGCCTTCCTCGAAGACACCCAGGATCCCCAAGATTTACACC
AAAACGGGAGACAAAGGGTTTTCTAGTACCTTCACAGGAGAAAGGAGACCCAAAGATGAC
CAAGTGTTTGAAGCCGTGGGAACTACAGATGAATTAAGTTCAGCTATTGGGTTTGCTCTG
GAATTAGTCACAGAAAAGGGCCATACATTTGCCGAAGAGCTTCAGAAAATCCAGTGCACA
TTGCAGGACGTCGGCTCGGCCCTGGCGACACCATGCTCCTCGGCCCGGGAGGCTCACTTA
AAGTATACCACGTTCAAGGCGGGGCCCATCCTGGAGCTGGAGCAGTGGATCGACAAGTAC
ACCAGCCAGCTCCCACCACTCACGGCCTTCATCCTGCCTTCGGGAGGCAAGATCAGCTCG
GCGCTGCATTTCTGCCGGGCCGTGTGCCGCCGGGCCGAGAGACGTGTGGTGCCTCTTGTC
CAGATGGGAGAGACCGATGCGAACGTGGCCAAGTTCTTAAACAGACTCAGTGACTATCTC
TTCACGCTAGCCAGATATGCAGCCATGAAGGAGGGGAATCAAGAGAAAATATACATGAAA
AATGACCCATCGGCCGAGTCTGAGGGACTCTGA

# Drug_Target_8_General_Function:
Involved in ATP binding

# Drug_Target_8_General_References:
12514191	Leal NA, Park SD, Kima PE, Bobik TA: Identification of the human and bovine ATP:Cob(I)alamin adenosyltransferase cDNAs based on complementation of a bacterial mutant. J Biol Chem. 2003 Mar 14;278(11):9227-34. Epub 2003 Jan 3.

# Drug_Target_8_HGNC_ID:
HGNC:19331

# Drug_Target_8_HPRD_ID:
07398

# Drug_Target_8_ID:
507

# Drug_Target_8_Locus:
12q24

# Drug_Target_8_Molecular_Weight:
27389

# Drug_Target_8_Name:
Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial

# Drug_Target_8_Number_of_Residues:
250

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF01923	Cob_adeno_trans

# Drug_Target_8_Protein_Sequence:
>Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial precursor
MAVCGLGSRLGLGSRLGLRGCFGAARLLYPRFQSRGPQGVEDGDRPQPSSKTPRIPKIYT
KTGDKGFSSTFTGERRPKDDQVFEAVGTTDELSSAIGFALELVTEKGHTFAEELQKIQCT
LQDVGSALATPCSSAREAHLKYTTFKAGPILELEQWIDKYTSQLPPLTAFILPSGGKISS
ALHFCRAVCRRAERRVVPLVQMGETDANVAKFLNRLSDYLFTLARYAAMKEGNQEKIYMK
NDPSAESEGL

# Drug_Target_8_Reaction:
(1) ATP + cob(I)yrinic acid a,c-diamide = triphosphate + adenosylcob(III)yrinic acid a,c-diamide

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Not Available

# Drug_Target_8_SwissProt_ID:
Q96EY8

# Drug_Target_8_SwissProt_Name:
MMAB_HUMAN

# Drug_Target_8_Synonyms:
Cob(I)alamin adenosyltransferase
Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial precursor
EC 2.5.1.17
Methylmalonic aciduria type B protein

# Drug_Target_8_Theoretical_pI:
8.78

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
16311595	Lerner-Ellis JP, Tirone JC, Pawelek PD, Dore C, Atkinson JL, Watkins D, Morel CF, Fujiwara TM, Moras E, Hosack AR, Dunbar GV, Antonicka H, Forgetta V, Dobson CM, Leclerc D, Gravel RA, Shoubridge EA, Coulton JW, Lepage P, Rommens JM, Morgan K, Rosenblatt DS: Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. Nat Genet. 2006 Jan;38(1):93-100. Epub 2005 Nov 27.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
MMACHC

# Drug_Target_9_GenBank_ID_Gene:
AL080062

# Drug_Target_9_GenBank_ID_Protein:
52545527

# Drug_Target_9_GeneCard_ID:
MMACHC

# Drug_Target_9_Gene_Name:
MMACHC

# Drug_Target_9_Gene_Sequence:
>849 bp
ATGGAGCCGAAAGTCGCAGAGCTGAAGCAGAAGATCGAGGACACGCTATGTCCTTTTGGC
TTCGAGGTTTACCCCTTCCAGGTGGCATGGTACAATGAACTCTTGCCTCCAGCCTTCCAC
CTACCGCTGCCAGGACCTACCCTGGCCTTCCTGGTACTCAGCACGCCTGCCATGTTTGAC
CGGGCCCTCAAGCCCTTCTTGCAGAGCTGCCACCTCCGAATGCTGACTGACCCAGTGGAC
CAGTGTGTGGCCTACCATCTGGGCCGTGTTAGAGAGAGCCTCCCAGAGCTGCAGATAGGA
ATCATTGCTGACTACGAGGTACACCCCAACCGACGCCCCAAGATCCTGGCCCAGACAGCA
GCCCATGTAGCTGGGGCTGCTTACTACTACCAACGACAAGATGTGGAGGCTGACCCATGG
GGGAACCAGCGCATATCAGGTGTGTGCATACACCCCCGATTTGGGGGCTGGTTTGCCATC
CGAGGGGTAGTGCTGCTGCCAGGGATAGAGGTGCCAGATCTGCCACCCAGAAAACCTCAT
GACTGTGTACCTACAAGAGCTGACCGTATCGCCCTACTCGAAGGCTTCAATTTCCACTGG
CGTGATTGGACTTACCGGGATGCTGTGACACCCCAGGAGCGCTACTCAGAAGAGCAGAAG
GCCTACTTCTCCACTCCACCTGCCCAACGATTGGCCCTATTGGGCTTGGCTCAGCCCTCA
GAGAAGCCTAGTTCTCCCTCCCCGGACCTTCCCTTTACCACACCCGCCCCCAAGAAGCCT
GGGAATCCCAGCAGAGCCCGGAGCTGGCTCAGCCCCAGGGTCTCACCACCTGCATCCCCT
GGCCCTTGA

# Drug_Target_9_General_Function:
Not Available

# Drug_Target_9_General_References:
Not Available

# Drug_Target_9_HGNC_ID:
HGNC:24525

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
3916

# Drug_Target_9_Locus:
1p34.1

# Drug_Target_9_Molecular_Weight:
31729

# Drug_Target_9_Name:
Methylmalonic aciduria and homocystinuria type C protein

# Drug_Target_9_Number_of_Residues:
282

# Drug_Target_9_PDB_ID:
Not Available

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
Not Available

# Drug_Target_9_Protein_Sequence:
>Methylmalonic aciduria and homocystinuria type C protein
MEPKVAELKQKIEDTLCPFGFEVYPFQVAWYNELLPPAFHLPLPGPTLAFLVLSTPAMFD
RALKPFLQSCHLRMLTDPVDQCVAYHLGRVRESLPELQIEIIADYEVHPNRRPKILAQTA
AHVAGAAYYYQRQDVEADPWGNQRISGVCIHPRFGGWFAIRGVVLLPGIEVPDLPPRKPH
DCVPTRADRIALLEGFNFHWRDWTYRDAVTPQERYSEEQKAYFSTPPAQRLALLGLAQPS
EKPSSPSPDLPFTTPAPKKPGNPSRARSWLSPRVSPPASPGP

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
May be involved in the binding and intracellular trafficking of cobalamin (vitamin B12)

# Drug_Target_9_SwissProt_ID:
Q9Y4U1

# Drug_Target_9_SwissProt_Name:
MMAC_HUMAN

# Drug_Target_9_Synonyms:
Not Available

# Drug_Target_9_Theoretical_pI:
7.92

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB00200
